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TAXANE-INDUCED MUSCULOSKELETAL PAIN IN WOMEN WITH OVARIAN 
CANCER 
Taxane-induced musculoskeletal pain (TIMP) is musculoskeletal pain that 
includes myalgia (i.e., diffuse muscle pain, usually accompanied by malaise) and/or 
arthralgia (i.e., joint pain) that occurs following treatment with taxane-based 
chemotherapy. TIMP is a symptom that is clinically reported as negatively affecting most 
cancer survivors receiving taxane-based chemotherapy; however, TIMP is not 
comprehensively understood. The purpose of this dissertation was to conduct a cross-
sectional, descriptive, correlational pilot study to describe TIMP in women with ovarian 
cancer who were being or had been treated with paclitaxel-containing regimens. Specific 
aims were to: (1) describe the TIMP symptom experience (intensity, distress, duration, 
location, quality, temporal pattern, aggravating and alleviating factors, and pain 
management); (2) describe the associations between TIMP (intensity, distress) and co-
occurring symptoms (pain [general], peripheral neuropathy, impaired sleep, fatigue, 
emotional distress, and/or hot flashes); and (3) identify associations between TIMP 
(intensity, distress) and patient-reported outcomes (interference with daily activities, 
physical functioning, and health-related quality of life). Primary data collection was 
performed on a convenience sample of 15 women with ovarian cancer. Participants 
were recruited from an outpatient cancer clinic, local cancer support communities, and a 
national cancer survivors’ research registry. Descriptive statistics and Spearman’s 
correlations were used.  
Findings showed TIMP is moderate to severe in intensity on average, constant, 
affecting a large area of the body, and aggravated by everyday walking. Greater TIMP 
intensity or distress was associated with greater intensity and interference of most co-
vi 
occurring symptoms and was associated with greater interference with daily activities, 
worse physical functioning, and worse health-related quality of life. Nurses are 
encouraged to comprehensively assess TIMP using structured, validated tools for pain 
to better intervene on aggravating and alleviating factors and pain management 
regimens. Prospective, longitudinal studies with larger sample sizes are needed to 
further understand TIMP and its impact on cancer survivors. 
Janet S. Carpenter, PhD, RN, FAAN, Co-chair 
Julie L. Otte, PhD, RN, OCN, Co-chair 
  
vii 
TABLE OF CONTENTS 
 
LIST OF TABLES .......................................................................................................... iix 
LIST OF FIGURES .......................................................................................................... x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
CHAPTER 1 ................................................................................................................... 1 
Significance ..................................................................................................................... 1 
TIMP and the TIMP Symptom Experience ............................................................... 1 
TIMP and Co-occurring Symptoms .......................................................................... 2 
TIMP and Patient-reported Outcomes ..................................................................... 3 
TIMP and Ovarian Cancer ....................................................................................... 4 
A Comprehensive Assessment to Increase Understanding of TIMP ........................ 5 
Topical Fit to National Priorities ............................................................................... 5 
Purpose and Specific Aims .............................................................................................. 6 
Approach ......................................................................................................................... 7 
Guiding Theoretical Frameworks and the Conceptual Model ................................... 7 
Design ..................................................................................................................... 8 
Sample .................................................................................................................... 8 
Study Procedures .................................................................................................... 9 
Analysis ......................................................................................................................... 16 
Data Entry and Management ..................................................................................16 
Data Analysis .........................................................................................................16 
Potential Problems and Alternative Solutions ................................................................ 19 
Conclusions and Future Research ................................................................................. 20 
References .................................................................................................................... 21 
CHAPTER 2 ..................................................................................................................31 
Conceptual Framework ................................................................................................. 32 
Purpose and Specific Aims ............................................................................................ 33 
Methods and Search Strategy ....................................................................................... 33 
Inclusion and Exclusion Criteria ..............................................................................33 
Data Abstraction .....................................................................................................34 
Results .......................................................................................................................... 35 
Critiquing the Evidence (Synthesis/Overall Purpose) ..............................................35 
Terms Describing TIMP (Aim 1) .............................................................................36 
Descriptions of the Symptom Experience (Aim 2) ...................................................37 
Contextual Variables Relating to TIMP (Aim 3) .......................................................38 
Status Outcomes of TIMP (Aim 4) ..........................................................................38 
Discussion ..................................................................................................................... 39 
Strengths and Limitations .............................................................................................. 42 
Conclusions ................................................................................................................... 44 
Implications for Practice ................................................................................................ 44 
References .................................................................................................................... 54 
CHAPTER 3 ..................................................................................................................60 
Methods ........................................................................................................................ 62 
Sample and Setting ................................................................................................62 
Study Procedures ...................................................................................................62 
Data Entry and Management ..................................................................................64 
Measures ...................................................................................................................... 64 
TIMP Symptom Experience ....................................................................................65 
Co-occurring Symptoms .........................................................................................67 
Data Analysis ................................................................................................................ 69 
viii 
TIMP Symptom Experience ....................................................................................69 
Co-occurring Symptoms .........................................................................................71 
Results .......................................................................................................................... 71 
Description of the Sample ......................................................................................71 
TIMP Symptom Experience ....................................................................................72 
Co-occurring Symptoms .........................................................................................75 
Discussion ..................................................................................................................... 75 
Implications for Nursing ................................................................................................. 80 
Conclusion .................................................................................................................... 81 
References .................................................................................................................... 93 
CHAPTER 4 ................................................................................................................ 100 
Background of the Problem ......................................................................................... 101 
Methods ...................................................................................................................... 102 
Design, Setting, and Participants .......................................................................... 102 
Data Collection ..................................................................................................... 102 
Measures .................................................................................................................... 102 
TIMP Intensity and Distress .................................................................................. 103 
Patient-reported Outcomes................................................................................... 103 
Data Analysis .............................................................................................................. 104 
TIMP Intensity and Distress .................................................................................. 104 
Patient-reported Outcomes................................................................................... 105 
Results ........................................................................................................................ 105 
TIMP Intensity and Distress .................................................................................. 105 
Patient-reported Outcomes................................................................................... 106 
Discussion ................................................................................................................... 106 
Strengths and Limitations ............................................................................................ 108 
Implications for Research to Advance Practice ............................................................ 109 
References .................................................................................................................. 114 
CHAPTER 5 ................................................................................................................ 120 
Synthesis of Key Findings ........................................................................................... 120 
Strengths and Limitations of the Dissertation ............................................................... 123 
Recommendations for Future Research ...................................................................... 124 
Conclusions ................................................................................................................. 125 
References .................................................................................................................. 127 
CURRICULUM VITAE  
  
ix 
LIST OF TABLES 
 
CHAPTER 1:  
None. 
 
CHAPTER 2:  
Table 2-1. Evaluation Matrix for Critiquing the Evidence (Synthesis/Overall Purpose) ... 48 
Table 2-2. Terms Describing TIMP (Aim 1)............................................................................. 52 
Table 2-3. Descriptions of the Symptom Experience (Aim 2) .............................................. 53 
 
CHAPTER 3: 
Table 3-1. Sample Demographic and Treatment Characteristics........................................ 86 
Table 3-2. Descriptive Statistics for TIMP Pain Intensity Questionnaire and Diary .......... 88 
Table 3-3. Body Locations where TIMP was Experienced by Participants ........................ 89 
Table 3-4. Descriptors Endorsed by Participants to Describe TIMP Quality ..................... 90 
Table 3-5. Descriptive Statistics for Other Symptom Measures .......................................... 91 
Table 3-6. Spearman Correlations between TIMP Intensity and Distress and Other 
Symptoms .................................................................................................................................... .92 
 
CHAPTER 4: 
Table 4-1. TIMP Phenotypes Based on BPI Intensity Ratings and Distress Ratings ..... 111 
Table 4-2. Spearman’s Correlations: TIMP Intensity and Distress with Patient-  
reported Outcomes ................................................................................................................... 112 
Table 4-3. Patient-reported Outcomes across Phenotypes for TIMP Intensity and 
Distress ....................................................................................................................................... 113 
 
CHAPTER 5: 
None. 
  
x 
LIST OF FIGURES 
 
CHAPTER 1: 
Figure 1-1. Multidimensional Symptom Assessmet Model for TIMP .................................... 8 
 
CHAPTER 2: 
Figure 2-1. Conceptual Framework .......................................................................................... 46 
Figure 2-2. Flow Diagram .......................................................................................................... 47 
 
CHAPTER 3: 
Figure 3-1. Study Accrual Flow Diagram ................................................................................. 82 
Figure 3-2. Patterns Endorsed by Participants to Describe Temporality of TIMP............. 83 
    
CHAPTER 4: 
None. 
 
CHAPTER 5: 
None. 
 
  
xi 
LIST OF ABBREVIATIONS 
Abbreviation  Term 
TIMP   Taxane-induced musculoskeletal pain 
IOM   Institute of Medicine 
NIH   National Institutes of Health 
NCI   National Cancer Institute 
NINR   National Institute of Nursing Research 
ACS   American Cancer Society 
ONS   Oncology Nursing Society 
IUSCC   Indiana University Simon Cancer Center 
IRB   Institutional Review Board 
DTQ   Demographic and Treatment Questionnaire 
SCQ   Self-Administered Comorbidity Questionnaire 
BPI   Brief Pain Inventory 
NPS-CIN  Neuropathy Pain Score-Chemotherapy Induced Neuropathy  
Specific 
PROMIS  Patient-Reported Outcomes Measurement Information System 
HFRDIS  Hot Flash Related Daily Interference Scale 
PF-10    Performance 10 
FACT-G  Functional Assessment of Cancer Therapy- General 
REDCap  Research Electronic Data Capture 
HIPAA   Health Insurance Portability and Accountability 
SPSS   Statistical Package for the Social Science 
M   Mean 
Mdn   Median 
SD   Standard Deviation 
 
1 
CHAPTER 1 
This chapter introduces the dissertation topic of taxane-induced musculoskeletal 
pain (TIMP) in women with ovarian cancer. The chapter provides a discussion of the 
significance of the topic, identifies the purpose and specific aims of the study, and 
outlines the study methods. In the subsequent chapters, the manuscripts related to this 
dissertation study are discussed. 
Significance 
TIMP and the TIMP Symptom Experience 
TIMP is musculoskeletal pain that includes myalgia (i.e., diffuse muscle pain, 
usually accompanied by malaise) and/or arthralgia (i.e., joint pain) that occurs following 
treatment with taxane-based chemotherapy. 1 It appears to affect more than half of 
patients treated with taxane chemotherapy agents such as paclitaxel.1 TIMP appears to be 
distinct from other common taxane-induced symptoms including peripheral neuropathy.2-14 
Peripheral neuropathy is neuropathic pain (i.e., sensory nerve involvement) with unusual 
or increased reaction to stimuli or loss of sensation (i.e., paresthesia and pain), 
characteristically occurring in the fingers and toes (i.e., “glove and stocking” distribution), 
persisting at rest or at night, and alleviated while walking.15-17 In contrast, TIMP is 
musculoskeletal pain aggravated by movement and likely has different clinical, 
somatosensory, and psychological parameters that distinguish it from peripheral 
neuropathy.15 Although chemotherapy-induced peripheral neuropathy is often reported as 
the most common taxane-related symptom, in at least one review, reports of TIMP closely 
approximated or exceeded the incidence of peripheral neuropathy.18 This has important 
clinical implications in that treatments targeting neuropathic pain (i.e., peripheral 
neuropathy) may need to be different from those targeting TIMP.19 
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The TIMP symptom experience is not comprehensively understood.2-13 In the 
investigator’s systematic review,20 out of 688 articles pertaining to taxane-based 
chemotherapy, only 12 studies (1.7%) included evaluable data related to TIMP.2-13 
Moreover, 10 of the 12 articles (83%) were clinical trials evaluating the safety, tolerability, 
and/or efficacy of taxane-based chemotherapy, with TIMP mentioned only as a side effect. 
2, 3, 5-11, 13  All studies assessed TIMP intensity only, using a limited (i.e., not 
comprehensive) toxicity grading method. No studies comprehensively assessed TIMP 
using the common symptom assessment parameters of intensity, distress, duration, 
location, quality, temporal pattern, aggravating and alleviating factors, and pain 
management even though pain literature suggests that practitioners evaluating pain for the 
first time should start with multidimensional instruments to obtain an overview of the 
symptom.21 Once core areas of the pain have been identified, then more specific, 
streamlined assessments can be used. Also, the investigator’s review supported the 
literature which suggests TIMP is likely common18, 22 – affecting up to 94% of patients20 - 
and intensity appears to be dose dependent with doses of paclitaxel > 200mg/m2 leading 
to more frequent and intense TIMP.23 However, other details of TIMP remain unstudied 
and unspecified. In other non-oncology populations, such as primary care patients, 
musculoskeletal pain is a significant problem. It is typically localized simultaneously in both 
the axial (head, neck and spine, ribs, and pelvis) and peripheral (extremities) skeleton.24 
Musculoskeletal pain can also arise from the muscles, ligaments, tendons, or joints and 
can be localized or generalized.25 These facts, from primary care patients, suggest there is 
more to be understood about TIMP than intensity ratings alone.   
TIMP and Co-occurring Symptoms 
TIMP likely co-occurs with symptoms such as general pain, peripheral neuropathy, 
impaired sleep, fatigue, emotional distress (i.e., depression and anxiety), and/or hot 
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flashes. Research on co-occurring cancer symptoms, or symptom clusters, suggests co-
occurring symptoms may not be independent entities, but rather symptoms that interact 
synergistically.26, 27 A current research priority, clusters of co-occurring symptoms have a 
greater adverse impact on outcomes than individual symptoms.26 Among all cancer 
survivors, frequent co-occurring symptoms include pain, impaired sleep, low 
energy/fatigue, depression, and anxiety.1, 26, 28-31 In addition to hot flashes, these symptoms 
have also been highlighted in studies specific to women with ovarian cancer. 32-35 
Prolonged or ineffective management of treatment-related symptoms can contribute to 
treatment noncompliance, worsening of symptoms, reduced health-related quality of life, 
and overall poorer patient outcomes.1 In non-oncology populations, such as primary care 
patients, pain and depression co-occur at a rate of 30-50%.36, 37 In addition, many primary 
care patients seeking treatment for pain report significantly impaired sleep, which is known 
to further aggravate pain, reduce pain inhibitory responses, increase emotional distress, 
and reduce well-being.38 Because TIMP has not been well researched, associations 
among TIMP and other co-occurring symptoms likely exist but are currently unspecified. 
TIMP and Patient-reported Outcomes 
TIMP is likely to be associated with patient-reported outcomes including greater 
interference with daily activities, poorer physical functioning, and lower health-related 
quality of life. Although research to date has not identified TIMP to be a dose-limiting 
toxicity, the myalgia and/or arthralgia experienced by patients receiving taxane-based 
chemotherapy can result in impaired mobility, secondary to the limitation of joint function, 
and the experience of pain can affect physical functioning.1 Though it has not been widely 
studied, TIMP very likely undermines cancer survivors’ health-related quality of life in ways 
that are similar to the burden of persistent musculoskeletal pain seen in non-oncology 
populations. Data from non-oncology populations suggest the following. Pain is among the 
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most common reasons for temporary and permanent work disability.39, 40 The World Health 
Organization recognizes the significant contribution of musculoskeletal conditions to the 
global burden of disease.38 Additionally, the Institute of Medicine (IOM) has highlighted the 
significant functional and economic effects of musculoskeletal pain.41 Musculoskeletal pain 
is the most common, disabling, and costly of all pain complaints.40 Pain is known to be 
even more prevalent in individuals with psychiatric comorbidity, specifically mood 
disorders, and is a strong predictor of both onset and persistence of depression; likewise, 
depression is a strong predictor of pain.42 Furthermore, the comorbidity of pain and chronic 
conditions, such as impaired sleep and emotional distress, decrease an individual’s active 
coping in addition to negatively impacting health-related quality of life, disability, and even 
response to treatment.36, 42 These facts suggest TIMP is likely negatively associated with 
patient-reported outcomes. However, because it has not been comprehensively studied, 
the strength of the associations among TIMP and interference with daily activities, physical 
functioning, and health-related quality of life are unknown.  
TIMP and Ovarian Cancer 
Women with ovarian cancer represent an ideal population for studying TIMP for 
three reasons. First, ovarian cancer affects over 21,000 American women annually, with 
over 190,000 survivors estimated to be living in the United States in 2012, and yet ovarian 
cancer survivors are poorly represented in cancer research.43, 44 Second, women with 
ovarian cancer do not take aromatase inhibitors, which cause musculoskeletal pain45-47 
and could confound understanding of TIMP. Third, women with ovarian cancer do not 
typically require prophylaxis with growth factor,48 which causes musculoskeletal 
symptoms1 and could confound understanding of TIMP.  
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A Comprehensive Assessment to Increase Understanding of TIMP 
A comprehensive assessment of TIMP is the first logical step in building symptom 
science towards greater understanding of this treatment-related symptom. To improve 
patient-reported outcomes in cancer care, control of cancer treatment-related symptoms 
such as TIMP is essential.28 However, clinical trials designed to prevent and treat 
symptoms require a foundational knowledge of the symptom experience as well as the 
type and strength of relationship with co-occurring symptoms and patient-reported 
outcomes. Specifically, the proposed research  addressed national priorities to generate 
new knowledge to alleviate symptom burden and improve functioning and health-related 
quality of life in persons affected by cancer by describing the TIMP symptom experience 
(Aim 1); examining the associations between TIMP (intensity, distress) and co-occurring 
symptoms (Aim 2); and examining the associations between TIMP (intensity, distress) and 
patient-reported outcomes (Aim 3) among women with ovarian cancer who were being or 
had been treated with paclitaxel-containing regimens. Findings are foundational for the 
investigator’s program of research in symptom science. Ultimately, the investigator plans 
to build upon her minor in epidemiology and conduct a larger, population-based, 
prospective, longitudinal study to expand understanding of TIMP to fully inform the 
development, timing, and testing of effective interventions to manage TIMP (e.g., 
National Institutes of Health [NIH] R01).   
Topical Fit to National Priorities 
This study addresses the important national research priority of symptom 
management set forth by the National Cancer Institute (NCI) Office of Cancer 
Survivorship,49 the National Institute of Nursing Research (NINR),50 the American Cancer 
Society (ACS),51 the IOM,52 and the Oncology Nursing Society (ONS).53, 54 Cancer and 
cancer treatment-related symptoms can profoundly affect an individual’s health-related 
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quality of life throughout survivorship.55 This study aligns with (1) the NCI Office of Cancer 
Survivorship’s mission to enhance quality of survival and minimize physical and 
psychosocial adverse effects of cancer and its treatment during survivorship;49 (2) NINR’s 
focus on symptom management research that will improve the understanding of symptom 
science and assist in developing new symptom management strategies to improve quality 
of life in chronic illness, including cancer;50 (3) ACS’s priority to improve health-related 
quality of life through symptom surveillance;51 (4) IOM’s priority for cancer care that is 
patient-centered in managing symptoms and side effects from treatment;52 and (5) ONS’s 
symptom management research priority to manage cancer symptoms and symptom 
clusters, as well as side effects related to cancer treatment.53, 54 Additionally, recognition of 
patient-reported outcomes, supported by the NIH, is of growing research interest and 
requires attention to standardized measurement of health-related quality of life outcomes 
in populations including cancer survivors.56-59 
Purpose and Specific Aims 
Given the limitations in our knowledge about TIMP, the next logical step was to 
carefully study TIMP, its co-occurring symptoms, and its relationship to patient-reported 
outcomes. Because paclitaxel is the most common treatment for women with ovarian 
cancer and because this group is a poorly represented cancer population, this proposal 
focuses on survivors of ovarian cancer. Therefore, the purpose of this cross-sectional, 
descriptive, correlational, pilot study was to describe TIMP in women with ovarian cancer 
who were being or had been treated with paclitaxel-containing regimens. Specific aims 
were to:   
Aim 1: Describe the TIMP symptom experience (intensity, distress, duration, temporal 
pattern, location, quality, aggravating and alleviating factors, and pain management);  
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Aim 2: Describe the associations between TIMP (intensity, distress) and co-occurring 
symptoms (pain [general], peripheral neuropathy, impaired sleep, fatigue, emotional 
distress, and/or hot flashes); 
Aim 3: Identify associations between TIMP (intensity, distress) and patient-reported 
outcomes (interference with daily activities, physical functioning, and health-related quality 
of life)   
Approach 
Guiding Theoretical Frameworks and the Conceptual Model 
The proposed research was guided by two well-established conceptual models 
with substantial empirical evidence for guiding this study60-64 (Figure 1-1, below). The 
Theory of Symptom Management and the Theory of Unpleasant Symptoms61, 63, 65 guide 
the symptom dimensions to be assessed (Aim 1), highlight the importance of evaluating 
co-occurring symptoms (Aim 2), and identify important patient-reported outcomes to be 
evaluated (Aim 3). Symptoms are subjective experiences reflective of changes occurring 
in physical functioning, sensations, or cognition, and they are the most frequent reason 
individuals seek health care.60, 61 Both theories emphasize essential symptom 
management concepts including, but not limited to, personal characteristics influencing 
symptoms and outcomes, descriptions of the symptom experience (intensity, distress, 
duration, location, quality, temporal pattern, aggravating or alleviating factors, and pain 
management, as well as co-occurring symptoms), and associations with patient-reported 
outcomes.61, 63, 65  
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Design 
This was a cross-sectional, descriptive, correlational pilot study which addressed 
specific Aims 1-3.  
Sample 
A convenience sample of 15 women were recruited from the cancer clinics at 
Indiana University. Data from the Indiana University Simon Cancer Center (IUSCC) clinics 
indicate 264 women with ovarian cancer were seen in the clinics in the last calendar year, 
assuring feasibility of recruitment even if accrual rates were as low as 8% in a one-year 
period or as low as 5% in an 18-month period.  
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Sample Criteria 
Inclusion criteria were: (1) > 21 years of age; (2) diagnosed with ovarian cancer; 
(3) have a history of no other cancer diagnoses (basal cell skin cancer will be allowed); (4) 
undergoing active treatment with paclitaxel (must have received at least one dose), or 
have received treatment with paclitaxel in the past; (5) report experiencing myalgia and/or 
arthralgia after starting paclitaxel treatment; (6) self-reported ability to read and speak 
English; and (7) willing and able to participate in the study. To eliminate confounding 
factors, exclusion criteria were: (1) confirmed bone metastases and/or (2) have received 
growth factor with their chemotherapy treatment.  
Study Procedures 
Institutional Review and Approvals  
 The investigator received IUSCC approval and IU Institutional Review Board (IRB) 
approval. Waivers of written informed consent and written authorization to use protected 
health information were sought from the IRB. A study information sheet was used to 
explain the study. 
Recruitment and Verbal Consent and Authorization 
 To recruit potential participants, the investigator and her designee worked with a 
medical oncology physician at the IUSCC. The investigator or her designee was available 
to meet with interested women during clinics. Potential participants were identified by the 
physician or his designees, who briefly introduced the study to potential participants in 
person at the end of their clinic visits and asked if they were interested in learning more 
about the study. If women agreed, the investigator or her designee entered the room to 
provide more detailed study-related information and answered questions. The investigator 
or her designee carefully reviewed the Study Information Sheet including the risks, 
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benefits, specific activities, and voluntary nature of the study and addressed any potential 
questions. Interested women were asked to provide verbal consent and verbal 
authorization to use protected health information before research staff conducted eligibility 
screening. Ineligible women were informed they were ineligible and thanked for their 
interest. Eligible women received a copy of the Study Information Sheet and completed 
data collection on site or received a web link to complete the study from home. The 
investigator and her designee tracked reasons for disinterest and ineligibility.  
 Additionally, the applicant worked with Rare Patent Voice, LLC©66 to recruit 
potential participants. Rare Patient Voice, LLC© is a research company focused on 
promoting health outcomes in patients with rare disorders. Rare Patient Voice, LLC© has a 
registry of over 900 ovarian cancer survivors who have agreed to be contacted for future 
studies.66 The investigator also used additional recruitment methods (see below Potential 
Problems and Alternative Solutions) because monthly accrual was not reached in the 
first three months. 
Data Collection  
Eligible women could take part in a study visit at the cancer clinic, preferably the 
same day recruitment occurred. At the visit, the investigator or her designee provided 
specific instructions to prevent participant confusion about which symptom was being 
evaluated in a given questionnaire. Women spent approximately 20 minutes completing 
questionnaires via a secure, web-based database. Women were given a TIMP Pain Diary 
with instructions for completing it during their next full cycle of paclitaxel (2 minutes each 
day for 28 days) and returning it in a pre-addressed, stamped envelope. If participants 
could not stay to complete the questionnaires, they received a web link to complete 
questionnaires at home (or given paper copies, if that was their preference, to take home 
to complete and return by mail with the TIMP Pain Diary). If eligible participants wanted to 
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speak to a member of the study team before agreeing to participate, they were contacted 
by the e-mail (e-mails were sent using IU Outlook) or telephone number provided on the 
Screening and Eligibility Form for follow up and additional information. If participants were 
agreeable to participating in the study after additional follow up, they either received a web 
link to complete questionnaires online at home or were mailed paper copies to be returned 
to the study team by mail. Participants received a $25 gift card for their time, effort, and 
any travel expenses incurred. Gift cards were mailed after the TIMP Pain Diaries (and 
other paper forms, if used) were returned. The investigator made reminder/troubleshooting 
calls and e-mails to those participants who do not return their diaries.  
Additionally, Rare Patient Voice, LLC© sent a mass e-mail message to their 
ovarian cancer registry explaining the study. A link to the study materials in the REDCap 
database was included in the mass e-mail message. Potential participants were able to 
download and review the Study Information Sheet as well as the Authorization Form so 
they could read more about the study, the requirements for participation, and be provided 
with contact information for follow up if necessary. If women chose to proceed, screening 
and eligibility questions were asked next. Based upon the potential participant’s 
responses, eligibility was determined within REDCap. Ineligible women received a 
message informing them they were ineligible and thanking them for their interest in the 
study. Eligible women were directed to the subsequent section where they acknowledged 
they were providing consent and authorization to use protected health information by 
clicking on appropriate buttons. Participants were guided through each of the 
questionnaires as they provided their responses by direct data entry. Upon completion of 
the questionnaires, participants were informed they must also complete the TIMP Pain 
Diary in order to complete the study and receive a gift card. Women were informed that 
daily e-mail links would be sent to them for the next 28 days. Daily links asked women to 
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record their pain intensity (morning and bedtime) for the previous day. After 28 days, when 
the diaries were completed, participants were mailed a $25 gift card at the mailing address 
provided in REDCap. Rare Patient Voice, LLC©  participants were given the option to forgo 
providing their mailing address if they chose to have their responses remain anonymous; 
however, this prohibited the study team from providing the participant with the gift card 
incentive as payment for their time and effort. This was explained in the initial mass e-mail 
message describing the study to potential participants. Finally, if Rare Patient Voice, LLC© 
participants provided their mailing address and symptom scores on questionnaires were 
elevated, participants were notified by letter accompanying the gift card incentive. The 
letter encouraged participants to follow up with their healthcare provider. Letters were not 
provided to those who chose to remain anonymous when completing the study. 
Measures 
Measures are described below. Special instructions were provided at the top of all 
TIMP-specific measures to prompt participants to focus on TIMP-specific pain.  
Person Characteristics 
Demographic information including site of recruitment, age, race/ethnicity, marital 
status, socio-economic status (employment and ability to pay for basics), education, and 
menopausal status was self-reported and recorded by participants using the Demographic 
and Treatment Questionnaire (DTQ). Disease and treatment-specific information including 
the dose and frequency of paclitaxel treatment (and the date of last treatment) and cancer 
information (date of cancer diagnosis, stage of disease, and dates and types of treatments 
including surgery, chemotherapy, and radiation) was also self-reported and recorded by 
participants using the DTQ. Comorbidities were evaluated using the Self-Administered 
Comorbidity Questionnaire (SCQ) modified. On this 12-item validated tool, respondents 
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mark “yes” or “no” as to whether they have each of 12 health conditions and, if yes, 
whether they are receiving treatment for it (yes/no) and whether it limits their activities 
(yes/no). A maximum of 3 points are given to conditions that are present, being treated, 
and limiting current activities. Therefore, higher scores indicate greater comorbidity. 
Cronbach’s alpha, including among cancer patients, was 0.94.67 This tool has been 
modified to include six additional conditions affecting women, including fibromyalgia, 
lupus, thyroid disease, seizures, headaches, and an option for “other.” Conditions that may 
impact reports of musculoskeletal pain (e.g., arthritis, fibromyalgia) were assessed. Finally, 
use of pain medications was assessed using 2 items on the Brief Pain Inventory (BPI) – 
Long Form.68 This 32-item validated tool for pain assesses use of pain medications (i.e., 
yes/no do you have pain requiring medication and an open-ended item where participants 
indicate names of treatments or medications used for pain), pain intensity, distress, 
duration, location, quality, aggravating or alleviating factors, and pain management in the 
past week. The BPI has been used in patients with pain related to chronic conditions (e.g., 
cancer, osteoarthritis, low back pain), or acute conditions (e.g., postoperative pain). 
Cronbach’s alpha has ranged from 0.77 to 0.91.68  
The TIMP Symptom Experience 
Intensity: Two methods were: (1) the mean of BPI items #1 to #468 and (2) TIMP 
Pain Diary prospective ratings of TIMP intensity at two daily time points (upon waking and 
before going to bed) over 28 days (one chemotherapy cycle).  Distress was measured 
using BPI item #5,68 which asked participants to rate distress caused by TIMP on a 0-10 
scale. Duration was assessed using the TIMP Pain Diary as the total number of days and 
the total number of nights with pain reported. Location was assessed by asking 
participants to shade relevant parts of BPI item #6,68 the body diagram. Quality was 
evaluated using BPI item #7,68 where participants circled adjectives to describe their TIMP. 
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Temporal pattern was evaluated using the TIMP Pain Diary intensity ratings over time. 
Aggravating/alleviating factors were assessed using BPI items #8 to #11,68 where 
participants open-endedly reported what makes their TIMP better or worse; indicated, on a 
0 to 100 scale, the percentage of relief from pain treatments or medications; and circled, 
from a list of possible choices, methods that relieved pain. Finally, pain management was 
evaluated using BPI items #12 to #14,68 which provided categorical options assessing 
period of pain relief provided by medications and frequency of pain medication. In addition, 
BPI items #15 to #1968 included yes/no items about pain management and BPI item #2068 
was an open-ended question about medications not prescribed by the doctor and taken for 
pain by the participant.  
Co-occurring Symptoms 
Pain (general): PROMIS – Pain Interference (General) – Short Form 8a, an 8-item 
validated tool for pain interference not related to TIMP (e.g., headache), this shortened 
tool correlated r=0.95 with items from the original tool. Item responses (1=not at all to 
5=very much) are summed and higher scores indicate greater pain interference. Alpha for 
scores that were +/- 2 standard deviations from the mean were 0.11 to 0.99.57 Peripheral 
neuropathy: Neuropathy Pain Score (Chemotherapy-Induced Neuropathy-Specific) (NPS-
CIN), is a 6-item validated tool for chemotherapy-induced peripheral neuropathy pain with 
Cronbach’s alpha=0.96. Item responses (0=not at all to 4=excruciating) are summed and 
higher scores indicate greater pain.69 Impaired sleep: PROMIS – Sleep Disturbance – 
Short Form 8a, is an 8-item validated tool. This shortened tool correlated r=0.96 with items 
from the original tool. Item responses (1=not at all to 5=very much) are summed and 
higher scores indicate greater sleep disturbance. Alpha for scores that were +/- 2 standard 
deviations from the mean were 0.88 to 0.97.57 Fatigue: PROMIS – Fatigue – Short Form 
8a, is an 8-item validated tool. This shortened tool correlated r=0.76 with items from the 
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original tool. Item responses (1=not at all to 5=very much) are summed and higher scores 
indicate greater fatigue. Alpha for scores that were +/- 2 standard deviations from the 
mean were 0.95 to 1.00.57 Emotional distress: PROMIS – Emotional Distress – Anxiety – 
Short Form 8a and the PROMIS – Emotional Distress – Depression – Short Form 8a are 
each 8-item scales. Each of these shortened tools correlated r=0.96 with items from the 
original tool. Item responses (1=not at all to 5=very much) are summed and higher scores 
indicate greater anxiety or depression. Alphas for scores that were +/- 2 standard 
deviations from the mean were 0.62 to 0.98 for anxiety and 0.47 to 0.99 for depression.57 
Hot flashes: The Hot Flash Related Daily Interference Scale (HFRDIS) is a 10-item scale 
measuring how much hot flashes interfere with 9 daily activities and quality of life over the 
past two weeks. Item responses (0 (not at all) to 10 (completely interfered) are summed 
and higher scores indicate greater hot flash interference.70 Cronbach’s alphas are 
consistently > .90.71  PROMIS measures are advantageous because they: (1) are from 
standardized scales that have been widely used in various populations, including 
cancer;57-59 (2) have been used in prior work conducted by Dr. Kroenke (committee 
member),72 both independently and in combination with the investigator; and (3) will 
allow for future comparison with other non-cancer populations. 
Patient-reported Outcomes 
Interference with daily activities associated with TIMP was evaluated using the 
arithmetic mean of the 7 BPI interference items.68 Cronbach’s alphas have ranged from 
0.77 to 0.9168 Physical functioning: The Performance 10 (PF10) is a valid and reliable 10-
item scale that is the physical functioning subscale of the MOS-SF-36, one of the most 
commonly used measures of health-related quality of life.73, 74 Cronbach’s alphas generally 
exceed 0.90.73, 74 Health-related quality of life: The Functional Assessment of Cancer 
Therapy-General (FACT-G) is a valid 28-item tool assessing physical well-being, 
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social/family well-being, emotional well-being, and functional well-being. Item responses 
(0=not at all to 4=very much) yield total scores ranging from 0 to 112, with higher scores 
indicating higher health-related quality of life. Cronbach’s alpha is 0.89.75 
Analysis 
Data Entry and Management 
Data was entered into a secure, web-based REDCap76 (Research Electronic Data 
Capture) database. Data not directly entered by participants was entered by the 
investigator and double-checked after two weeks elapsed. REDCap servers are secure 
and aligned with Health Insurance Portability and Accountability Act (HIPAA) regulations. 
REDCap incorporates real-time validation rules (with automated data type and range 
checks) at the time of entry. Prompts alerted the respondent if any items were missed. 
Data was exported for analysis to SPSS® version 24. Case summaries detected missing 
items or out-of-range values. Only diaries with at least 90% of all possible ratings were 
used, as previously done in Dr. Carpenter’s (Co-chair) studies.77-79  
Data Analysis 
Person characteristics were evaluated using frequencies (nominal/ordinal) and 
descriptive statistics (interval/ratio). Information was used to describe the sample in the 
dissertation publications.  
Aim 1 Analysis 
Aim 1 Analysis: Describe the TIMP symptom experience (intensity, distress, 
duration, location, quality, temporal pattern, aggravating and alleviating factors, and pain 
management). Descriptive statistics, including frequencies, percentages, mean, median, 
mode, standard deviations, and 95% confidence intervals, were produced to describe 
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each dimension of the symptom experience. Intensity: BPI intensity ratings were reported 
as mean, median, mode, standard deviation, and range. TIMP Pain Diary ratings were 
reported as morning, nighttime, and combined mean, median, mode, standard deviation, 
and range for the 28 days. Distress: Individual scores on this 0-10 scale were analyzed 
and presented as mean, median, mode, standard deviation, and range. Duration: TIMP 
Pain Diary intensity ratings across 56 possible time points (28 days x 2 daily time points) 
were presented as a total overall percentage of time points where pain was present. For 
example, women rating intensity > 1 at all 56 time points (28 days x 2 daily time points) 
would score as pain duration 100%, those with ratings > 1 on 28 of 56 time points as pain 
duration 50%. If only morning or night pain was recorded, the duration was considered to 
be one-half day. Location: The body diagram was divided into 8 sections including: (1) 
anterior head and neck; (2) posterior head and neck; (3) anterior thorax; (4) posterior 
thorax; (5) right shoulder, arm, elbow, forearm, wrist, hand; (6) left shoulder, arm, elbow, 
forearm, wrist, hand; (7) right hip, thigh, knee, leg, ankle, foot; and (8) left hip, thigh, knee, 
leg, ankle, foot. Frequencies and percentages were calculated in accordance with 
categorical variables for both the total number of areas reported by the women and the 
number of women reporting pain in each area. Quality: BPI descriptors endorsed were 
given a value of 1. This allowed calculation of percentages of women who endorsed each 
descriptor, the ability to summarize the top 3 to 5 descriptors, and total the number of 
descriptors endorsed (mean, median, standard deviation, range). Temporal pattern: The 
mean weekly morning and nighttime intensity ratings (with 95% confidence intervals) were 
graphed over time for the entire sample as well as each individual. Aggravating and 
alleviating factors: Answers to categorical and BPI open-ended questions were coded 
using basic content analysis to develop commonly occurring categorical themes and 
analyzed by frequencies and percentages. Percentages of BPI pain relief ratings were 
described as such, along with frequencies and mean, median, standard deviation, and 
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range. Pain management: BPI questions 12 to 14 were analyzed according to 
frequencies and percentages for the categorical options given for period of pain relief 
provided by medications and frequency of pain medication. Questions 15 to 19 were 
coded categorically and were evaluated using frequencies and percentages. Question 20 
was analyzed using basic content analysis to develop commonly occurring categorical 
themes for classes and/or names of specific medications, which were further described by 
frequencies and percentages. Coding for all content analyses used in the Aim 1 analysis 
were verified by Drs. Carpenter (Co-chair) and Otte (Co-chair) and disagreements 
resolved through discussion.   
Aim 2 Analysis 
Aim 2 Analysis: Describe the associations between TIMP (intensity, distress) and 
co-occurring symptoms (pain [general], peripheral neuropathy, impaired sleep, fatigue, 
emotional distress, and/or hot flashes).  Spearman’s correlations were used to measure 
the magnitude of the relationships among TIMP (intensity, distress) and pain (general) 
interference, peripheral neuropathy intensity, impaired sleep intensity, fatigue intensity, 
emotional distress (i.e., anxiety and depression) intensity, and hot flash interference. 
Means, standard deviations, and correlations were reported. Positive correlations 
indicated that greater TIMP intensity and/or distress was correlated with greater (i.e., 
worse) intensity or interference of co-occurring symptoms. The magnitude (r), direction 
(+/), and significance (p value) of each relationship were described.  
Aim 3 Analysis 
Aim 3 Analysis: Identify associations between TIMP (intensity, distress) and 
patient-reported outcomes (interference with daily activities, physical functioning, and 
health-related quality of life). As shown in Figure 1-1 above, TIMP intensity and distress 
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were evaluated in relation to outcomes (interference with daily activities, physical 
functioning, and health-related quality of life). Spearman’s correlations were used to 
measure the magnitude of the relationships among TIMP intensity and distress and 
interference with daily activities, physical functioning, and health-related quality of life. 
Means, standard deviations, and correlations were reported. Positive correlations 
indicated that greater TIMP intensity and/or distress was correlated with greater 
interference with daily activities, physical functioning, and/or health-related quality of life. 
The magnitude (r), direction (+/-), and significance (p value) of each relationship were 
described. Correlations involving FACT-G total scores will be completed with and without 
the FACT-G pain item to identify if conceptual overlap occurs when including the pain 
item. If so, this item will be removed from FACT-G total scores for the analyses.   
Potential Problems and Alternative Solutions 
  Additional recruitment methods included expanding recruitment to other sites in 
the Indianapolis area. Participants could also self-refer to the study by telephoning the 
project office. This occurred if patients were referred by physicians or in response to local 
cancer care clinics and ovarian community support groups who had the study’s 
advertisement available for pick-up, posted the advertisement, and/or shared study 
contact information with ovarian cancer survivors during routine communications. 
Physicians could also directly refer patients by telephoning the project office. Also, 
organizations such as the American Cancer Society, Little Red Door, Cancer Support 
Community, and Ovar’Coming Together were contacted. If agreeable, these 
organizations distributed the flyer and/or the same mass e-mail used for the Rare Patient 
Voice, LLC© registry to advertise the study. Potential participants were able to self-refer 
and complete eligibility questions by clicking the REDCap link provided in the e-mail.  
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Conclusions and Future Research 
This was the first study to fully characterize the symptom experience, co-occurring 
symptoms, and patient-reported outcomes of TIMP in ovarian cancer survivors. Findings 
from the proposed study provide an important foundation for the investigator’s program of 
research in symptom science. Ultimately, the investigator plans to build upon her minor in 
epidemiology and conduct a larger, population-based, prospective, longitudinal study to 
expand understanding of TIMP to fully inform the development, timing, and testing of 
effective interventions to manage TIMP (e.g., NIH R01).   
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CHAPTER 2 
This chapter focuses on the state of the science of TIMP and serves as a call to 
action for a comprehensive understanding of TIMP and suggests cancer nurses must 
contribute to national initiatives to improve patient-reported outcomes by addressing TIMP 
symptom management needs and associated health-related quality of life outcomes in 
cancer survivors.  
Total cancer mortality in the United States has declined and, thus, cancer 
survival rates have improved correspondingly.1, 2 However, increased survivorship is 
offset by multiple, persistent treatment-related symptoms.3 Taxane-induced 
musculoskeletal pain (TIMP) is defined as arthralgia (i.e., joint pain) and/or myalgia (i.e., 
diffuse muscle pain, usually accompanied by malaise) related to the administration of 
taxane-based chemotherapy.4 Paclitaxel is one of the most widely prescribed taxane 
agents in clinical practice and is predominately administered in populations of breast, 
ovarian, and non-small cell lung cancer.5 Across all populations of paclitaxel-treated 
patients, TIMP is likely common6, 7 and intensity appears to be dose dependent with 
doses of paclitaxel > 200mg/m2 leading to more frequent and intense TIMP.4 However, 
other common symptom assessment parameters such as distress, timing, quality, and 
concurrence (i.e., co-occurring symptoms) of TIMP appear to be unstudied and 
unspecified and, although TIMP is likely common,6, 7 true estimates of TIMP prevalence 
appear to be unknown.  
In other non-oncology patient populations, such as those seen in primary care 
settings, musculoskeletal pain is a significant problem. It is typically localized 
simultaneously in both the axial (head, neck and spine, ribs, and pelvis) and peripheral 
(extremities) skeleton, affecting both areas of the body.8 Musculoskeletal pain can also 
arise from the muscles, ligaments, tendons, or joints and can be localized or generalized.9 
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These facts regarding persistent musculoskeletal pain in primary care suggest there is 
more to be understood about TIMP that is not adequately captured by intensity ratings 
alone. Because TIMP may importantly affect the health-related quality of life of cancer 
survivors, careful and comprehensive research examination of TIMP is warranted.4, 10, 11 
Conceptual Framework 
To improve both health-related quality of life and patient-reported outcomes in 
cancer care, control of cancer treatment-related symptoms, such as TIMP, is essential.12 
Symptoms are subjective experiences reflective of changes occurring in biophysical 
functioning, sensations, or cognition, and they are the most frequent reason individuals 
seek health care.13, 14 The University of California San Francisco Theory of Symptom 
Management and Lenz’s Theory of Unpleasant Symptoms are well-established 
theoretical frameworks with substantial empirical evidence for guiding a comprehensive 
assessment addressing the complexity of symptoms.13-17 These two theories are 
particularly suitable for guiding symptom management research in populations including 
those diagnosed with cancer.14, 15, 17 Both theories emphasize essential symptom 
management concepts including, but not limited to, contextual considerations (i.e., 
person, environment, health, and illness variables), descriptions of the symptom 
experience (i.e., intensity, distress, timing, quality, and concurrence variables), and the 
impact of symptoms on selected outcomes (i.e., health-related quality of life, functional 
status, emotional status, need for additional treatment, and discontinuation of treatment 
or dose adjustment).13, 14, 16, 18 Thus, both the University of California San Francisco 
Theory of Symptom Management and Lenz’s Theory of Unpleasant Symptoms provide 
comprehensive and theoretical symptom assessment frameworks appropriate for 
guiding research, and they were combined to develop a conceptual framework which 
guided this review. See Figure 2-1. In this framework, four types of contextual variables 
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such as person variables (e.g., age) or illness variables (e.g., comorbid conditions) may 
influence the experience of TIMP, which may, in turn, influence outcomes.  
Purpose and Specific Aims 
Therefore, because it is imperative that symptom research reflects the complex 
nature of symptoms, the purpose of our paper was to systematically review the literature 
examining the state of the science around TIMP. Specific aims were to evaluate: (1) the 
conceptual clarity of TIMP; (2) descriptions of the TIMP symptom experience, including 
intensity, distress, timing, quality, and symptom concurrence; (3) contextual variables 
influencing TIMP including person, environment, health, and illness variables; and (4) 
the impact of TIMP on selected outcomes including health-related quality of life, 
functional status, emotional status, need for additional treatment, and discontinuation of 
treatment or dose adjustment. Findings from the review would therefore help to better 
delineate the framework (see Figure 2-1).  
Methods and Search Strategy 
Inclusion and Exclusion Criteria 
Relevant studies addressing TIMP were identified using a comprehensive and 
systematic approach. Inclusion criteria were: full-text articles, published in a peer-
reviewed journal; population specific to adult cancer survivors aged 18 and older; 
evaluated TIMP; and English language. Exclusion criteria were: case reports, review 
articles, cost-effectiveness trials, study populations including metastatic patients or 
patients with bone metastasis (i.e., patients diagnosed with Stage IV cancer), and 
studies including regimens with treatments or therapeutic interventions having known 
skeletal side effects (such as aromatase inhibitors or growth factor). The rationale for 
exclusion was to ensure that any reported arthralgia or myalgia could be exclusively 
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attributed to the taxane agent rather than to metastases or other forms of therapy. 
Studies evaluating neuropathy (peripheral nerve pain) were also excluded. No limits 
were placed on year published and the search was current as of August 4, 2014. Peer-
reviewed literature was searched using the PubMed database. The search terms used 
were (pain or myalgia or arthralgia or musculoskeletal) and taxane and neoplasm. 
Reference lists of all relevant review articles were searched for additional, applicable 
citations (i.e., “spooling”) before being excluded.  
Articles were identified for inclusion by the primary author. A subset (2%) of 
articles were discussed with both co-authors before being eliminated for not meeting 
inclusion criteria. As shown in Figure 2-2, 688 articles were identified and their titles and 
abstracts screened for exclusion. Of these, 676 were excluded, leaving a total of 12 
articles. Common reasons for exclusion were a failure to address or report TIMP, sample 
populations comprised of participants with bone metastasis, and sample populations 
comprised of participants classified as metastatic, whether or not stage or site of 
metastases was reported.  
Data Abstraction 
The data were abstracted and organized into five separate tables consistent with 
the review aims. All abstracted data were verified by a second reviewer. The first table 
used in the analysis included a general overview of the studies including: focus (TIMP or 
toxicity as a primary vs. secondary focus), type of taxane (docetaxel; paclitaxel; or 
nanoparticle, albumin-bound paclitaxel), dose and frequency of taxane, other 
chemotherapy regimen agents assessed and premedications administered (when 
discussed), cancer type(s), number of subjects, and specification of time points for TIMP 
data collection. The second table used during analysis included all identified terms 
describing TIMP, consistent with Aim 1. The third table showed the dimension(s) of the 
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symptom experience (intensity and measure used, distress, timing, quality, and 
symptom concurrence) addressed for each TIMP term used (Aim 2). If symptom 
intensity was assessed for a given TIMP term(s), measures used to evaluate intensity 
were listed in the table. The fourth table (Aim 3) listed person variables (demographic, 
psychological, sociological, and physiological), environment variables (situational, 
physical, social, and cultural), and health and illness variables (risk factors, injuries, or 
disabilities), the contextual variables that might influence TIMP. The fifth table used 
during the analysis (Aim 4) showed the impact of TIMP on selected outcomes including 
health-related quality of life, functional status, emotional status, requirement of additional 
treatment, and discontinuation of treatment or dose adjustment. Only data from the first 
three of these five tables are reported in this paper because so few of the included 
studies evaluated contextual variables influencing TIMP or the impact of TIMP on the 
pre-specified, selected outcomes. See Tables 2-1- 2-3.  
Results 
Critiquing the Evidence (Synthesis/Overall Purpose) 
As shown in Table 2-1, a very limited number of studies were identified.19-30 Most 
studies were conducted in the United States,19, 21, 25, 28, 29 42% (n = 5), or Europe,20, 22, 24, 
27, 30 42% (n = 5). Year published ranged from 1997 to 2013, with 83% (n = 10) of studies 
published in the year 2000 or later. Studies were evenly split relative to focus, with 50% 
(n = 6) having a primary focus on TIMP or cancer treatment-related toxicity21, 26-30 and 
50% (n = 6) having a secondary focus on TIMP or treatment-related toxicity.19, 20, 22-25  
Paclitaxel was the most commonly evaluated taxane agent, used in 83% (n = 10) 
of studies.19-21, 23, 24, 26-30 Docetaxel was used in 8% (n = 1),22 and nanoparticle, albumin-
bound paclitaxel was used in 8% (n = 1) of studies.25 Paclitaxel was administered at 
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doses greater than 200mg/m2 in 33% (n = 4) of the studies.19, 27-29 The most frequently 
administered dose of paclitaxel was 175mg/m2, given in 42% (n = 5) of studies.20, 23, 24 ,26, 
30 When specified, cycles of paclitaxel were usually administered every 21 days (every 3 
weeks).19, 20, 22-30 Across all studies, there was an average of two additional 
chemotherapy regimen agents assessed (range = 0-5). Only two studies23, 30 evaluated 
paclitaxel alone, and no other oral or intravenous chemotherapy regimen agents. 
Premedications were described in 58% (n = 7) of studies19, 23, 24 ,27-30 and included 
dexamethasone, diphenhydramine, chlorpheniramine, and cimetidine as well as other 
non-specified H2 receptor antagonists and corticosteroids. 
Breast cancer was the most commonly evaluated cancer type, assessed in 42% 
(n = 5) of studies.20-22, 25, 29 Other cancer types included ovarian, assessed in 25% (n = 3) 
of studies,23, 26, 30 non-small cell lung cancer (25%, n = 3),19, 27, 28 and small-cell lung 
cancer (8%, n = 1).24 Half of studies (n = 6) had sample sizes of 35 or fewer,19, 21, 23-25, 30 
and half (n = 6) had sample sizes greater than 50.20, 22, 26-29 Time points for collecting 
assessments of TIMP, reported in 50% (n = 6) of studies,21, 23, 25, 27-29 varied across this 
subset; 2 (17%)23, 25 occurred after each chemotherapy cycle, 2 (17%)27, 29 occurred 
throughout chemotherapy cycles, 1 (8%)21 occurred during the last cycle of 
chemotherapy, and 1 (8%)28 occurred after 2 cycles of pre-operative chemotherapy and 
again after 3 cycles of post-operative chemotherapy. The studies specifying that 
assessments of TIMP were collected throughout chemotherapy cycles27, 29 did not 
specify the exact intervals the assessments of TIMP were collected. 
Terms Describing TIMP (Aim 1) 
As shown in Table 2-2 (Aim 1), 6 different terms (adverse event, complication, 
side effect, symptom, syndrome, and toxicity) were used to describe TIMP. Although the 
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individual studies used from 1 to 5 different terms, TIMP was described as a toxicity in 
92% (n = 11).19, 20, 22-30  
Descriptions of the Symptom Experience (Aim 2) 
As shown in Table 2-3 (Aim 2), 83% (n = 10) of studies19, 20, 22-28, 30 used the terms 
arthralgia and/or myalgia to signify TIMP. Across studies, the average number of terms 
used to signify TIMP was 2.6 (range = 2-4). Other less commonly used terms for TIMP 
included bone pain and/or joint pain, used in 25% (n = 3) of studies.21, 25, 29 
No studies evaluated all dimensions of the TIMP symptom experience. Intensity 
was measured in all studies, most commonly with the National Cancer Institute Common 
Toxicity Criteria, used in 50% (n = 6) of studies.19, 25-29 The World Health Organization 
Dose Limiting Toxicity scale was used in 33% (n = 4) of studies.20, 23, 24, 30 Intensity 
severity ranged from mild (Grade 1) to life-threatening (Grade 4). Among the terms 
arthralgia, myalgia, and bone pain, TIMP was estimated across the various studies to 
affect from 1.3% to 94% of study subjects. The intensity measure was not specified in 
17% (n = 2) of studies.21, 22 In one study29 there was a conceptual-operational mismatch 
between the terms arthralgia and myalgia and the results from a linear analog scale for 
flu-like symptoms, and therefore intensity grading was not reported for these TIMP 
terms. Distress was reported in only 8% (n = 1) of studies.21 Similarly, timing, for only 
three of four total TIMP terms used, was addressed in only 8% (n = 1) of studies,29 and 
quality was addressed in only 8% (n = 1) of studies.21 Concurrence (co-occurring 
symptoms) was not addressed by any of the studies included in our review.  
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Contextual Variables Relating to TIMP (Aim 3) 
Person, health, and illness domains influencing TIMP were addressed in only 
17% (n = 2) of studies.26, 29 No physical, social, or cultural variables comprising the 
environment domain were evaluated by any study included in our review.  
Of those reporting person domains potentially influencing TIMP, one study26 
found arthralgia and myalgia caused by paclitaxel did not vary between older and 
younger groups of patients. This finding suggests that age may not be a risk factor for 
treatment-related symptom severity (p = .57) in women with ovarian cancer undergoing 
chemotherapy. Another study29 addressed the influence of physiological variables (also 
within the person domain) by evaluating plasma levels of inflammatory cytokines in 
relation to incidence and timing of musculoskeletal pain in breast cancer patients 
receiving chemotherapy. Increases in interleukin (IL)-10 correlated strongly and 
positively with joint pain (p = .003) in those who received weekly paclitaxel. In the 3-
weekly paclitaxel group, IL-8 correlated positively with “flu-like” symptoms (p = .008).29 
This same study29 was also the only study to assess risk factors relating to TIMP by 
addressing correlations among paclitaxel, the release of inflammatory cytokines, and 
musculoskeletal symptoms, and their findings suggested that inflammatory cytokine 
release induced by paclitaxel may be a risk factor for musculoskeletal symptoms in 
breast cancer patients who are undergoing treatment with taxane-based chemotherapy.  
Status Outcomes of TIMP (Aim 4) 
No studies addressed all of the outcomes of TIMP specified in our model. Most 
studies did not address health-related quality of life outcomes at all, and only 8% (n = 1) 
of studies partially addressed these outcomes.21 This study,21 which partially addressed 
health-related quality of life outcomes, was a qualitative evaluation of symptoms 
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experienced by women undergoing chemotherapy and descriptions of how treatment-
related symptoms, including bone pain while on paclitaxel, affected quality of life 
emerged as a major theme and was discussed. This same study21 was also the only 
study to partially address functional status (8%) and emotional status (8%). Additional 
treatment for TIMP was addressed in 17% (n = 2) of the studies, including intravenous 
analgesics23 and non-steroidal analgesics.24 Non-steroidal analgesics were reported to 
be effective in managing complaints of TIMP;24 efficacy of intravenous analgesics was 
not reported.23 Discontinuation of treatment or dose adjustment was a reported 
consequence in only 17% (n = 2) of studies.23, 25 Discontinuation of treatment was 
reported in one study,23 for one participant receiving paclitaxel, secondary to severe 
arthralgia and myalgia, and another study25 found that dose reduction was required for 
one participant with complaints of severe myalgia from nanoparticle, albumin-bound 
paclitaxel.  
Discussion 
Our review of the very limited research on TIMP had four major findings. First, 
research to date has involved inconsistent use of terms signifying TIMP, and this lack of 
conceptual clarity has been impeding our understanding of true estimates of prevalence 
of this cancer treatment-related symptom. Second, assessment of TIMP has largely 
been limited to symptom intensity. Third, most research to date has not examined 
contextual variables influencing TIMP, and fourth, most research to date has not 
evaluated the impact of TIMP on outcomes. Each of these findings is discussed below. 
First, research to date has been inconsistent in its use of terms to signify TIMP. 
Conceptual clarity is necessary to move forward with cancer symptom management 
research regarding the assessment of TIMP; for a concept such as TIMP to be solid and 
strong, it must clearly name that to which it refers (there must not be an excess of terms 
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referring to TIMP), it must be clearly defined, and its use in theory should be clear so 
that anyone can understand exactly what is being described, explained, or predicted.31 
In most current research, arthralgia and myalgia may be listed separately or alone or 
these terms may even be grouped with a common neurotoxicity known as 
chemotherapy-induced peripheral neuropathy.4 Chemotherapy-induced peripheral 
neuropathy may appear to be similar to arthralgia and myalgia in that it is pain caused by 
many of the same chemotherapy agents; however, chemotherapy-induced peripheral 
neuropathy includes sensory nerve involvement with unusual or increased reaction to 
stimuli or a loss of sensation (paresthesias and pain).32 Furthermore, these symptoms 
commonly occur in the fingers and toes, thus presenting with a characteristic “glove and 
stocking” distribution.33 Inconsistent use of TIMP terms and a lack of research defining 
and differentiating TIMP from chemotherapy-induced peripheral neuropathy perpetuates 
a lack of conceptual clarity surrounding TIMP and has, in some cases, precluded notions 
regarding the relevancy of non-neuropathic pain components (TIMP) associated with 
chemotherapy. In turn, this negatively impacts health care providers’ ability to assess 
and manage TIMP effectively in clinical practice. These assertions are supported by a 
recent exploratory study34 evaluating symptom patterns indicative of neuropathic or 
musculoskeletal pain, or both, in cancer patients; one major finding was that, although 
chemotherapy-induced neuropathy-associated pain is usually regarded as neuropathic, 
movement-associated pain in approximately 60% of patients points to a musculoskeletal 
pain component as evidenced by a subgroup of patients with different clinical, 
somatosensory, and psychological parameters. Furthermore, one characteristic of 
musculoskeletal pain is its association with weight bearing or physical exercise which is 
different from persisting pain occurring at rest or at night that alleviates while walking 
and is characteristic of neuropathic pain.34 Interestingly, anxiety was higher in patients 
with musculoskeletal pain components which could be explained by anxiety as a known 
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risk factor for musculoskeletal pain where activation of the sympathetic nervous system 
releases stress hormones leading to impairment of muscle functioning essential for 
control of movements and posture.34, 35 Therefore, one can infer that true estimates of 
prevalence cannot be determined without conceptual clarity of TIMP, and the recognition 
of TIMP as separate and distinct from other types of treatment-related pain as has been 
suggested by recent literature. 
Second, most research has involved a limited evaluation of TIMP. Assessment of 
TIMP in our review was largely limited to symptom intensity. Indeed, this finding supports 
literature suggesting that most models of symptoms focus on one symptom and, 
specifically, on the intensity of the symptom and not on its other features, such as 
distress, timing, quality, or concurrence.17 Theoretical models such as the Theory of 
Symptom Management and the Theory of Unpleasant Symptoms, which helped to 
define our conceptual framework for this review, demonstrate the importance of fully 
evaluating all dimensions of the symptom experience in order to comprehensively 
understand a symptom and to inform the development of efficacious interventions. No 
studies comprehensively assessed TIMP using the common symptom assessment 
parameters of distress, timing, quality, and concurrence even though pain literature 
suggests health care providers evaluating pain for the first time should start with 
multidimensional instruments to obtain an overview of the symptom.36 Once core areas of 
the pain have been identified, then more specific, streamlined assessments (i.e., intensity 
and interference with functional status, only) can be used. Finally, it is important to note 
that addressing the dimension of symptom concurrence (both commonly co-occurring 
symptoms and the concept of cancer treatment-related symptom clusters) is a current 
research priority.15, 37-40 Therefore, more thorough reporting of all symptom experience 
dimensions of TIMP is critical.  
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Finally, studies did not examine contextual variables influencing TIMP or address 
the impact of TIMP on selected outcomes. Person, environment, health, and illness 
variables serve as a reminder of the contextual considerations potentially capable of 
influencing symptoms.14 Therefore, these contextual variables must be evaluated in 
research on TIMP. To illustrate, a woman’s experience of TIMP may vary according to 
her age, reproductive status, and genetic risk factors (person domain); cultural beliefs 
about the meaning of her symptom or whether she is evaluated in a clinic or her home 
(environmental domain); and her current state of health or diagnosis (health and illness 
domains).14 Similarly, outcomes (both positive and negative) must also be assessed in 
evaluations of TIMP. Even when a disease is treated and/or controlled (survivorship), 
symptoms can remain a continued concern.13 Research suggests that symptoms may be 
associated with work impairments, resulting in a loss of work days or increased worker 
compensation.13, 16 Overall, the lack of research addressing both contextual variables 
and outcomes relative to TIMP limits the ability of scientists and clinicians to understand 
the full impact of TIMP in cancer survivors undergoing taxane-based chemotherapy 
treatment.  
Strengths and Limitations 
To the best of our knowledge, this is the first comprehensive review to synthesize 
the literature on TIMP. However, there were limitations to our review. First, only the 
PubMed database was searched for relevant studies and it is possible that some articles 
were missed. PubMed provides access to bibliographic information including over 24 
million citations and MEDLINE.41 The PubMed database was selected because 
biomedical topics and the sciences are the primary foci of articles contained in this 
database and these content areas directly related to the topic for this systematic review. 
Thus, it was reasonable to believe our search strategy effectively captured most, if not 
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all, of the evidence regarding TIMP and any additional articles that may have been 
acquired from searching a database other than PubMed, such as CINAHL, would not 
significantly alter the overall conclusions of our review. However, a larger review 
including multiple databases is likely needed to ascertain the full extent of this literature. 
Second, most studies were conducted in the United States19, 21, 25, 28, 29 or 
Europe,20, 22, 24, 27, 30 which limits the generalizability of our findings. International studies 
were retrieved from the search strategy previously described and were considered for 
inclusion in our review. Of note, these studies were eliminated on the basis of the pre-
specified exclusion criteria; the inclusion of growth factor in treatment regimens was the 
primary indication for exclusion of these studies. Third, the population for most studies 
was predominately female as breast cancer was the most commonly evaluated cancer 
type20-22, 25, 29 and ovarian cancer was the second most commonly evaluated cancer type. 
23, 26, 30 Because paclitaxel is predominately administered in populations of breast, 
ovarian, and non-small cell lung cancer, it was not surprising sample populations were 
mostly female. Therefore, gender may prove an important demographic variable in 
evaluating TIMP. 
Finally, two studies21, 25 included in our review used the term bone pain in their 
assessment of treatment-related symptoms. Because these studies also included the 
terms myalgia and joint pain (terms highly consistent with the definition of 
musculoskeletal pain), they were included in our review. It is possible that the 
assessments from these studies may have additionally included measurement of a 
different symptom (i.e., bone pain). However, this limitation does not significantly detract 
from the important findings of our review regarding the limited nature of research on 
TIMP. In particular, research to date has involved inconsistent use of terms signifying 
TIMP, which has impeded our understanding of true estimates of prevalence; 
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assessment of TIMP has largely been limited to symptom intensity; most research to 
date has not examined contextual variables influencing TIMP; and most research to date 
has not evaluated the impact of TIMP on outcomes.  
Conclusions 
TIMP is a treatment-related symptom that oncology health care providers need to 
address in order to improve health-related quality of life in cancer survivors undergoing 
taxane-based chemotherapy. In research on TIMP, there has been little consistency in 
terms, and measurement has largely been limited to toxicity grading scales. Overall, little 
is known about TIMP. Future research should focus on comprehensive descriptions of 
TIMP, including evaluation of all dimensions of the symptom experience as well as the 
contextual variables influencing TIMP and the impact of TIMP on outcomes in cancer 
survivors. Consideration should be given to type of taxane agent (preferably with an 
emphasis on paclitaxel since it is the most commonly prescribed), as well as to the type 
of cancer to be evaluated. Sample populations with minimal confounding influences on 
the experience of musculoskeletal pain should be evaluated, at first, in order to capture 
the richest and most clear picture of TIMP possible. It is only with information gleaned 
from this type of foundational and multidimensional research that new strategies for 
better management of TIMP can be developed, our understanding of the mechanisms 
underlying TIMP can be improved, and the role that TIMP likely assumes in the cancer 
treatment-related symptom clusters (both known and unknown) that are experienced by 
cancer survivors undergoing taxane-based chemotherapy can be clearly elucidated.  
Implications for Practice 
Recognition of patient-reported outcomes, supported by the National Institutes of 
Health, is of growing research interest and requires attention to health-related quality of life 
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outcomes in populations including cancer survivors.11, 42 Cancer and cancer treatment-
related symptoms can profoundly affect an individual’s health-related quality of life 
throughout their survivorship trajectory.10 In order to improve patient-reported outcomes in 
cancer care, control of treatment-related symptoms is essential. Further research about 
TIMP will address national priorities for generating new knowledge to advance symptom 
science. Importantly, these national priorities include the National Cancer Institute’s Office 
of Cancer Survivorship mission to enhance the quality of survival and minimize the 
physical and psychosocial adverse effects of cancer and its treatment that are 
experienced during survivorship in persons with cancer,43 and the National Institute of 
Nursing Research Strategic Plan priority of Advancing Quality of Life through symptom 
management.44 Comprehensive assessment of and research about TIMP will address 
several national priorities for generating new knowledge to advance symptom science and 
will be directly relevant to the care of cancer survivors undergoing taxane-based 
chemotherapy. Oncology nurses must contribute to national initiatives to improve patient-
reported outcomes by addressing the symptom management needs and health-related 
quality of life outcomes of cancer survivors. 
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Figure 2-1: Conceptual Framework
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Figure 2-2: Flow Diagram 
 
 
  
  
4
8 
Table 2-1: Evaluation Matrix for Critiquing the Evidence (Synthesis/Overall Purpose) 
 
Author, year, 
country 
Focus Type of Taxane Dose and 
frequency 
Other 
chemotherapy 
regimen agents 
assessed and 
premedications 
administered (when 
discussed) 
Cancer 
type 
n Time 
points 
specified  
1
° 
2
° 
Doce-
taxel 
Pacli- 
taxel 
Paclitaxel 
protein -
bound 
particles; 
albumin -
bound 
Altorki et al., 
(2003), US19 
 X  X  225 mg/m2 q 
21 days x 2 
cycles 
carboplatin, 
celecoxib 
 
dexamethasone, 
diphenhydramine, 
H2 receptor 
antagonist 
NSCLC n = 29, 
38% 
female 
 
Boccardo et 
al., (2010), 
Italy20 
 X  X  175 mg/m2 q 3 
weeks x 4 
cycles 
epirubicin, 
cyclophosphamide, 
methotrexate, 5 – 
fluorouracil, and 
vinorelbine 
Breast n = 
244, 
100% 
female 
 
Boehmke & 
Dickerson, 
(2005), US21 
X   X  Dose and 
frequency NS; 
4 cycles 
adriamycin and 
cyclophosphamide  
Breast n = 20, 
100% 
female 
28 weeks 
post-
diagnosis 
(during 
the last 
cycle of 
chemo) 
Bulent et al., 
(2013), 
Turkey22 
 X X   100 mg/m2 q 3 
weeks x 3 
cycles or 75 
mg/m2 q 3 
cyclophosphamide, 
doxorubicin, 5- 
fluorouracil, and 
epirubicin 
Breast n = 
539, 
100% 
female 
 
  
4
9 
weeks x 4 
cycles 
Gallardo -
Rincon et 
al., (2003), 
Mexico23 
 X  X  175 mg/m2 q 3 
weeks x 3- 6 
cycles 
None 
 
dexamethasone, 
chlorpheniramine, 
cimetidine 
Ovarian n = 30, 
100% 
female 
Toxicity 
recorded 
after each 
cycle (q 3 
weeks) 
and 
expressed 
as 
percenta-
ge of 149 
total 
cycles 
Gatzemeier 
et al., 
(1997), 
Germany24 
 X  X  175 mg/m2 q 3 
weeks; total # 
cycles NS 
carboplatin and oral 
etoposide 
 
premedications 
given but not 
specified 
SCLC n = 35, 
13% 
female 
 
Kaklamani et 
al., (2012), 
US25 
 X   X 260 mg/m2 q 3 
weeks x 4 
cycles 
oral lapatinib Breast n = 30, 
100% 
female 
Toxicity 
recorded 
after each 
cycle (q 3 
weeks) 
and 
expressed 
as 
percenta-
ge of total 
sample/ 
grade 
  
5
0 
Kurtz et al., 
(2011), 
International 
group26 
X   X  175 mg/m2 q 3 
weeks x 6 or 
more cycles 
carboplatin and 
pegylated 
liposomal 
doxorubicin 
Ovarian n = 
157, 
100% 
female 
 
O’Brien et 
al., (2003), 
Netherlands 
27 
X   X  200 mg/m2 q 
21 days x 3 
cycles 
Carboplatin 
 
dexamethasone, 
diphenhydramine, 
cimetidine 
NSCLC n = 57, 
33% 
female 
Toxicity 
monitored 
througho-
ut chemo 
and 
expressed 
as 
percenta-
ge (over 
all cycles) 
of total 
sample/ 
grade 
Pisters et al., 
(2000), US28 
X   X  225 mg/m2 q 
21 days x 2 
cycles pre-op 
and 3 cycles 
post-op 
Carboplatin 
 
dexamethasone, 
diphenhydramine, 
H2 receptor 
antagonist 
NSCLC n = 94, 
31% 
female 
Toxicity 
expressed 
as 
percenta-
ge of total 
sample/ 
grade at 
pre-op 
and post-
op chemo 
Pusztai et 
al., (2003), 
US29 
X   X 
(n = 
70) 
 225 mg/m2 q 
three weeks 
(# cycles NS) 
or 175 mg/m2 
q 3 weeks (# 
cycles NS) or 
cyclophosphamide, 
doxorubicin, and 5- 
fluorouracil (n = 20) 
 
dexamethasone, 
diphenhydramine, 
Breast N = 
105 
 
n = 90, 
100% 
female 
Toxicity 
monitored 
througho-
ut chemo 
and 
expressed 
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1 
80 mg/m2 
weekly (# 
cycles NS) 
cimetidine 
(paclitaxel groups) 
and 
dexamethasone, 
ondansetron, 
lorazepam (non-
paclitaxel group) 
(brea-
st 
cancer
); n = 
15, 
100% 
female 
healt-
hy 
contr-
ols 
as change 
in 
intensity 
over one 
cycle 
Trope et al., 
(1997), 
Norway and 
Sweden30 
X   X  175 mg/m2 q 3 
weeks x 6 to 
9 cycles 
None 
 
corticosteroids, 
diphenhydramine, 
and cimetidine 
Ovarian n = 35, 
100% 
female 
 
Abbreviations: US = United States, blank = not addressed, X = addressed, q = every, x = for, NSCLC = non-small cell lung  
cancer, NS = not specified, # = number, SCLC = small cell lung cancer  
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Table 2-2: Terms Describing TIMP (Aim 1) 
Abbreviations: X = term used, blank = term was not used 
  
 
First Author, and year Adverse 
event 
Complication Side effect Symptom Syndrome Toxicity 
Altorki, 200319 X     X 
Boccardo, 201020   X   X 
Boehmke, 200521    X   
Bulent, 201322      X 
Gallardo-Rincon, 200323      X 
Gatzemeier, 199724   X   X 
Kaklamani, 201225 X     X 
Kurtz, 201126   X   X 
O’Brien, 200327      X 
Pisters, 200028  X    X 
Pusztai, 200329 X  X X X X 
Trope, 199730      X 
  
5
3 
Table 2-3: Descriptions of the Symptom Experience (Aim 2) 
Abbreviations: X = addressed, NCI = National Cancer Institute Common Toxicity Criteria, blank = not addressed, WHO = World  
Health Organization Dose Limiting Toxicity, NS = not specified, LAS = Linear Analog Score
 
First Author, and Year Terms Used Intensity Distress Timing Quality Concurrence 
Altorki, 200319 myalgia/arthralgia X; NCI     
Boccardo, 201020 arthralgia/myalgia X; WHO     
Boehmke, 200521 bone and joint pain X; NS X  X  
Bulent, 201322 arthralgia/myalgia X; NS     
Gallardo-Rincon, 200323 myalgia/arthralgia X; WHO     
Gatzemeier, 199724 arthralgia/myalgia X; WHO     
Kaklamani, 201225 bone pain 
myalgia 
X; NCI     
Kurtz, 201126 arthralgia/myalgia X; NCI     
O’Brien, 200327 arthralgia 
myalgia 
motor toxicity 
X; NCI 
X; NCI  
X; NCI 
    
Pisters, 200028 myalgia/arthralgia X; NCI     
Pusztai, 200329 muscle aches 
joint pain 
flu-like symptoms 
 
muscle aches/pain 
 
 
X; LAS 
 
 
 
X; NCI 
in 30-day diary (n = 30) 
 X 
 
X 
 
X 
 
  
Trope, 199730 arthralgia/myalgia X; WHO     
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CHAPTER 3 
This chapter presents results from the dissertation research study, “Taxane-
induced Musculoskeletal Pain in Women with Ovarian Cancer,” and provides a 
description of the symptom experience and the associations with co-occurring 
symptoms. 
More than 22,000 women in the United States are newly diagnosed with ovarian 
cancer each year.1, 2 Treatment for ovarian cancer generally consists of surgery and 
chemotherapy and although many women respond well to these treatments initially, the 
majority experience disease recurrence after the first-line therapy, requiring ongoing 
chemotherapy treatment.3-5 Because there have been few appreciable therapeutic 
breakthroughs (i.e., intraperitoneal chemotherapy, dose dense paclitaxel, and the 
addition of bevacizumab) over the last ten years, discussions between patients and 
providers about quality of life vs. length of life have become increasingly important. Prior 
work demonstrates women with advanced or recurrent ovarian cancer would be willing 
to accept reductions in progression-free survival time in return for improvements in 
chemotherapy side effects.6 As such, management of cancer treatment-related 
symptoms is an essential component of cancer care7 to improve health-related quality of 
life especially in ovarian cancer where women are living with active disease.  
One cancer treatment-related symptom affecting women with ovarian cancer is 
taxane-induced musculoskeletal pain (TIMP). TIMP is musculoskeletal pain that includes 
myalgia (i.e., diffuse muscle pain, usually accompanied by malaise) and/or arthralgia (i.e., 
joint pain) that affects more than half of patients following treatment with taxane-based 
chemotherapy agents such as paclitaxel.8 A recent systematic review suggested the TIMP 
symptom experience is not comprehensively understood.9 The review included 12 
available studies. Most (83%) were clinical trials evaluating the safety, tolerability, and/or 
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efficacy of taxane-based chemotherapy, with TIMP mentioned only as a side effect and 
not fully described.10-21 Specifically, the review revealed that the TIMP symptom 
experience has not been comprehensively assessed using the common parameters of 
intensity, distress, duration, location, quality, temporal pattern, aggravating and alleviating 
factors, and pain management. Literature suggests that providers evaluating pain for the 
first time should start with multidimensional instruments to obtain an overview of the 
symptom.22 Once core areas of the pain have been identified, then more specific, 
streamlined assessments can be used. These gaps in the literature suggest there is more 
to be understood about TIMP and its impact on the patient experience.  
 Although TIMP is not well understood, it likely co-occurs with other symptoms 
commonly affecting cancer survivors. Research on co-occurring cancer symptoms, or 
symptom clusters, suggests co-occurring symptoms may not be independent entities, but 
rather symptoms that interact synergistically.23-26 Among all cancer survivors, frequent co-
occurring symptoms include pain, impaired sleep, low energy/fatigue, depression, and 
anxiety.7, 8, 23, 26-29 These symptoms as well as hot flashes have also been highlighted in 
studies specific to women with ovarian cancer.30-33 Prolonged or ineffective management 
of treatment-related symptoms can contribute to treatment noncompliance, worsening of 
symptoms, reduced health-related quality of life, and overall poorer patient outcomes.8 
Because TIMP has not been well researched, associations among TIMP and other co-
occurring symptoms likely exist but are currently unspecified.  
Ovarian cancer survivors are an ideal population for studying TIMP because they 
(1) are poorly represented in cancer symptom research, (2) often receive paclitaxel 
throughout survivorship, (3) frequently report TIMP, and (4) rarely receive other 
medications that are also known to cause treatment-related musculoskeletal pain (e.g., 
aromatase inhibitors, growth factor therapy).34-40 Therefore, the purpose of this cross-
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sectional, pilot study was to obtain preliminary data to describe TIMP and associations 
between TIMP (intensity, distress) and other co-occurring symptoms in women with 
ovarian cancer who were being or had been treated with paclitaxel-containing regimens. 
Methods 
Sample and Setting 
A convenience sample of women with ovarian cancer were recruited from an 
outpatient cancer clinic in the Midwest, local cancer support communities, and a national 
cancer survivors’ research registry between December 1, 2015 and October 14, 2016. 
Eligible subjects were: (1) > 21 years of age; (2) diagnosed with ovarian cancer; (3) had a 
history of no other cancer diagnoses (basal cell skin cancer was allowed); (4) undergoing 
active treatment with paclitaxel (must have received at least one dose) or received 
treatment with paclitaxel in the past; (5) experiencing myalgia and/or arthralgia after 
starting paclitaxel treatment; (6) able to read and speak English; (7) willing and able to 
participate in the study; (8) without bone metastases; and (9) not using and did not 
anticipate using growth factors with chemotherapy. The latter two were to avoid other 
known sources of musculoskeletal pain in this population.  
Study Procedures 
The study was approved by the university Scientific Review Committee (SRC) and 
Institutional Review Board (IRB). A waiver of written informed consent and written 
authorization to use protected health information for screening and data collection was 
granted. All women received study information and provided verbal informed consent and 
verbal authorization to use protected health information before being screened for 
eligibility. Completion of study measures confirmed their consent to participate in the 
study.  
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Women were recruited in three ways. First, during a clinic visit, a member of the 
research team identified potential participants, briefly introduced the study, assessed 
interest, and obtained verbal consent and authorization before completing eligibility 
screening. Second, a member of the research team contacted local support communities 
who agreed to send e-mail blasts to potentially eligible women and post flyers on 
research and communication boards. Interested women self-referred to the study and the 
above procedures to share study information, assess interest, and complete screening 
were done electronically, online. Third, a member of the research team contacted a 
national research registry, Rare Patient Voice, LLC©, which agreed to send e-mail blasts 
to potentially eligible women.41 Rare Patient Voice, LLC© is a registry of people who 
have agreed to be contacted about participating in research studies. Interested women 
self-referred to the study and the above procedures were done electronically, online. 
Eligible women received study measures in one of two ways. Those recruited 
from clinic had the option to receive paper copies of the study information sheet, 
questionnaires, and daily pain diary which they could fill out in the clinic or at home and 
return in a pre-paid mailer. They also had the option to fill out measures electronically, 
online. Those recruited via community agencies or Rare Patient Voice, LLC©  only had 
the option to fill out measures electronically. Those women who chose to complete 
measures electronically did so by receiving a web-based link to a secure Research 
Electronic Data Capture (REDCap) data collection database, which was included in the e-
mail blast.42 Those who completed online questionnaires and agreed to complete the 
online pain diary received daily e-mails for 28 days to remind them to complete the diary.  
Participants received a $25 gift card for their time and effort upon completion of the 
TIMP Pain Diary. Women who did not want to provide their name and mailing address or 
did not complete the TIMP Pain diary did not receive the gift card.  
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Data Entry and Management 
Data were entered into the secure, web-based REDCap database.42 Data not 
directly entered by participants was entered by the study team and double-checked after 
two weeks had elapsed. REDCap servers are secure and aligned with HIPAA regulations. 
REDCap incorporates real-time validation rules (with automated data type and range 
checks) at the time of entry. Data were exported for analysis to SPSS® version 24. Only 
diaries with at least 90% of all possible ratings were used.  
Measures 
Demographic and treatment information were self-reported, and were not verified 
against medical records. Demographics included age, race, ethnicity, marital status, 
employment status, socio-economic status, education, and menopausal status. 
Treatment information included date of diagnosis, stage of cancer, total number of 
chemotherapy cycles planned and received, chemotherapies received and currently 
taking, other treatments received for ovarian cancer diagnosis (i.e., surgery and/or 
radiation), and date of last paclitaxel treatment. 
Comorbidities were evaluated using the 12-item validated Self-Administered 
Comorbidity Questionnaire (SCQ) modified. Respondents marked “yes” or “no” as to 
whether they had each of 12 health conditions and, if yes, whether they were receiving 
treatment for it (yes/no) and whether it limited their activities (yes/no). A maximum of 3 
points are given to conditions that are present, being treated, and limiting current activities. 
Therefore, higher scores indicate greater comorbidity. Cronbach’s alpha, including among 
cancer patients, was 0.94.43 This tool was modified to include six additional conditions 
affecting women, including fibromyalgia, lupus, thyroid disease, seizures, headaches, and 
an option for other. 
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TIMP Symptom Experience 
The 32-item validated Brief Pain Inventory – Long Form assessed use of pain 
medications (i.e., yes/no do you have pain requiring medication) and pain intensity, 
distress, duration, location, quality, aggravating or alleviating factors, and pain 
management. The BPI has been used in patients with pain related to chronic conditions 
(e.g., cancer, osteoarthritis, low back pain), or acute conditions (e.g., postoperative pain). 
Cronbach’s alpha has ranged from 0.77 to 0.91.44 
The TIMP Pain Diary is a standard 28-day symptom reporting diary. Participants 
were asked to report their morning and nighttime TIMP on a scale of 0 (not at all intense) 
to 10 (extremely intense). Women who completed the diary on paper forms were asked 
to fill it out twice per day (once in the morning to reflect the previous night’s pain and 
once in the evening to reflect the day’s pain). Those who completed the diary 
electronically provided ratings for the previous day and night at the same time. 
Additionally, participants were asked to check yes/no did you receive paclitaxel 
chemotherapy today. Those women who were not on active treatment while completing 
the diary checked “no” for all 28 days of the TIMP pain diary.  
Intensity. BPI intensity ratings (on a 0-10 scale) were comprised of the worst, 
least, and average pain in the past week as well as current pain both at the individual item 
level and as the BPI total score (i.e., the average of all four BPI intensity items). 
Participants were asked to do their best to provide these intensity ratings in thinking only 
about their TIMP and not in thinking about any other types of daily pain (e.g., headache) 
not related to TIMP that they may have been experiencing. There were also TIMP Pain 
Diary prospective ratings of TIMP intensity (on a 0-10 scale) upon waking and before 
going to bed.  
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Distress. Distress was measured using a single item which asked participants to 
rate distress caused by TIMP on a 0-10 scale.  
Duration. Duration was assessed using the TIMP Pain Diary and reported as the 
total number of days and the total number of nights with pain reported. TIMP Pain Diary 
intensity ratings across 56 possible time points (28 days x 2 daily time points) were 
analyzed as a total overall percentage of time points where pain was present. For 
example, women rating intensity > 1 at all 56 time points (28 days x 2 daily time points) 
would score as pain duration 100%, those with ratings > 1 on 28 of 56 time points as pain 
duration 50%. If only morning or nighttime pain was recorded, the duration was considered 
to be one-half day (i.e., 1 time point).  
Location. Location was assessed by asking participants to shade relevant parts of 
the BPI body diagram. The body diagram was divided into 8 sections including: (1) anterior 
head and neck; (2) posterior head and neck; (3) anterior thorax; (4) posterior thorax; (5) 
right shoulder, arm, elbow, forearm, wrist, and hand; (6) left shoulder, arm, elbow, forearm, 
wrist, and hand; (7) right hip, thigh, knee, leg, ankle, and foot; and (8) left hip, thigh, knee, 
leg, ankle, and foot. 
Quality. Quality was assessed using the BPI which asked participants to endorse 
adjectives describing their TIMP. BPI descriptors endorsed were given a value of 1. This 
allowed calculation of percentages of women who endorsed each descriptor, the ability to 
summarize the top 3 to 5 descriptors, and the total number of descriptors endorsed.  
Temporal Pattern. Temporal pattern was assessed using the 28-day TIMP Pain 
Diary morning, nighttime, and combined intensity ratings over time. 
Aggravating/alleviating Factors. Aggravating/alleviating factors were assessed 
using several questions from the BPI and included: (1) open-ended participant responses 
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indicating what makes their TIMP better or worse; (2) responses indicating, on a 0 to 100 
scale, the percentage of relief from pain treatments or medications; and (3) responses 
indicating, by selecting from a list of possible choices, methods relieving pain.  
Pain Management. Pain management was also assessed using several questions 
from the BPI and included: (1) categorical options assessing period of pain relief provided 
by medications and frequency of pain medication; (2) yes/no items about pain 
management; and (3) an open-ended question about medications not prescribed by the 
doctor, but taken for pain.  
Co-occurring Symptoms 
PROMIS – Pain Interference (General) – Short Form 8a, is an 8-item validated tool 
that was used to assess for pain interference, which is considered an important pain-
related dimension that complements intensity ratings, 45 not related to TIMP. Participants 
were asked to do their best to provide pain interference ratings in thinking only about their 
other types of everyday pain not related to TIMP (e.g., headache), and not in thinking 
about their TIMP. Item responses (1=not at all to 5=very much) are summed and higher 
scores indicate greater pain interference. This shortened tool, tested in populations with a 
variety of diseases including cancer, correlated r=0.95 with items from the original tool and 
alphas for scores +/- 2 standard deviations from the mean were 0.11 to 0.99.46  
Neuropathy Pain Score (Chemotherapy-Induced Neuropathy-Specific) (NPS-CIN), 
is a 6-item validated tool that has been used to measure chemotherapy-induced peripheral 
neuropathy pain. Item responses (0=not at all to 4=excruciating) are summed and higher 
scores indicate greater pain. Cronbach’s alpha was 0.96 in a sample of cancer patients 
receiving taxane (i.e., paclitaxel or docetaxel) or platinum chemotherapy (i.e., cisplatin, 
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oxaliplatin, or carboplatin) and included multiple cancer types (breast, lung, 
gastrointestinal, head and neck, genitourinary, gynecologic, and “other”).47  
PROMIS – Sleep Disturbance – Short Form 8a, is an 8-item validated tool used to 
assess sleep disturbances. Item responses (1=not at all to 5=very much) are summed and 
higher scores indicate greater sleep disturbance. This shortened tool, tested in populations 
with a variety of diseases including cancer, correlated r=0.96 with items from the original 
tool. Alphas for scores +/- 2 standard deviations from the mean were 0.88 to 0.97.46  
PROMIS – Fatigue – Short Form 8a, is an 8-item validated tool used to measure 
fatigue. Item responses (1=not at all to 5=very much) are summed and higher scores 
indicate greater fatigue. This shortened tool, tested in populations with a variety of 
diseases including cancer, correlated r=0.76 with items from the original tool. Alphas for 
scores +/- 2 standard deviations from the mean were 0.95 to 1.00.46  
PROMIS – Emotional Distress – Anxiety – Short Form 8a, is an 8-item scale used 
to assess anxiety. Item responses (1=not at all to 5=very much) are summed and higher 
scores indicate greater anxiety. This shortened tool, tested in populations with a variety of 
diseases including cancer, correlated r=0.96 with items from the original tool. Alphas for 
scores +/- 2 standard deviations from the mean were 0.62 to 0.98.46 
PROMIS – Emotional Distress – Depression – Short Form 8a, is an 8-item scale 
used to assess depression. Item responses (1=not at all to 5=very much) are summed and 
higher scores indicate greater depression. This shortened tool, tested in populations with a 
variety of diseases including cancer, correlated r=0.96 with items from the original tool. 
Alphas for scores +/- 2 standard deviations from the mean were 0.47 to 0.99.46  
The Hot Flash Related Daily Interference Scale (HFRDIS) is a 10-item scale 
measuring how much hot flashes interfere with nine daily activities and quality of life over 
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the past two weeks. Item responses (0 (not at all) to 10 (completely interfered) are 
summed and higher scores indicate greater hot flash interference.48 Cronbach’s alphas, in 
both cancer patients and healthy women, are consistently >.90.49   
Cronbach’s alphas for the standardized questionnaires that were used in this study 
were not performed due to the fact that this was a pilot study with a small sample size and 
any reported alphas would likely be unreliable. 
Data Analysis 
A description of the sample was analyzed using descriptive statistics appropriate 
for the level of measurement (i.e., means, standard deviations, frequencies, and 
percentages). Person characteristics were evaluated using frequencies and descriptive 
statistics. For both the TIMP symptom experience and co-occurring symptoms analyses, 
missing data points were handled by exclusion of cases pairwise.50 
TIMP Symptom Experience 
Intensity. BPI intensity ratings were analyzed as mean, median, mode, standard 
deviation, and range. TIMP Pain Diary ratings were analyzed for morning, nighttime, and 
combined mean, median, mode, standard deviation, and range for the 28 days. Intensity 
ratings were also examined in relation to BPI cutpoints of mild (0-4), moderate (5-6), and 
severe (7-10) pain.51 
Distress. Distress was analyzed as mean, median, mode, standard deviation, and 
range.  
Duration. Duration as a total overall percentage of time points where pain was 
present (e.g., women rating TIMP intensity > 1 at all 56 time points [28 days x 2 daily time 
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points] would score as having constant pain with a duration of pain at 100% of recorded 
time points) was evaluated using frequencies and percentages.  
Additionally, commonly occurring phenotypes were developed to group women 
according to intensity and distress of their reported TIMP. Frequencies and percentages 
where analyzed to develop the emerging phenotypes (i.e., mild, mild to moderate, 
moderate to severe, severe, or variable mix of intensities and distress). Similarly, across 
the dimensions, patterns of intensity, distress, and duration of TIMP were also analyzed 
using frequencies and percentages. 
Location. Frequencies and percentages were calculated in accordance with 
categorical variables for both the total number of areas (mean, median, mode, standard 
deviation, and range) reported by the women and the total number of women reporting 
pain in each area.  
Quality. Frequencies and percentages were analyzed for women who endorsed 
each descriptor and the top 3 to 5 descriptors. The total number of descriptors endorsed 
were analyzed as mean, median, mode, standard deviation, and range.  
Temporal Pattern. Temporal patterns for morning, nighttime, and combined TIMP 
were graphed over time for the entire sample as well as each individual. 
Aggravating/alleviating Factors. Answers to categorical and BPI open-ended 
questions were coded using basic content analysis to develop commonly occurring 
categorical themes (total number of themes and range) and were analyzed by frequencies 
and percentages. Percentages of BPI pain relief ratings were described as such, along 
with frequencies and mean, median, mode, standard deviation, and range. 
Pain Management. Questions evaluating period of pain relief were analyzed 
according to frequencies and percentages for the categorical options given for period of 
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pain relief provided by medications and frequency of pain medication. Questions 
evaluating pain management were coded categorically (yes/no) and evaluated using 
frequencies and percentages. Open-ended responses about medications not prescribed 
by the doctor and taken for pain were analyzed using basic content analysis to develop 
commonly occurring categorical themes for classes and/or names of specific medications, 
which was further described by frequencies and percentages. Coding for all content 
analyses used in the TIMP symptom experience analysis were verified by the authors and 
disagreements were resolved through discussion.   
Co-occurring Symptoms 
Spearman’s correlations were used to assess the relationships between TIMP 
intensity and distress and co-occurring symptoms. Positive correlations indicated greater 
TIMP intensity or distress was correlated with greater (i.e., worse) intensity or interference 
of co-occurring symptoms.  
Results 
Description of the Sample 
Figure 3-1 shows the accrual flow from the 432 women who self-referred to the 
study or were approached for participation in the study to those who completed baseline 
questionnaires and the TIMP Pain Diary. The sample size for this pilot study included a 
total of 15 participants completing baseline questionnaires and 11 of those also 
completing the 28-day TIMP Pain Diary. Of the 15 women who participated in the study, 
n=3 were recruited from the cancer clinic and n=12 were recruited from either the Rare 
Patient Voice, LLC© registry or local cancer support communities. The low clinic 
recruitment was due to changes in physician coverage and a reduction in the patient 
volume seen at the clinic.  
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Women were on average 56 years of age. As shown in Table 3-1, most were 
non-Hispanic, White, married or living with a partner, retired from work, and had 
completed some years toward an undergraduate degree. Most had a diagnosis of stage 
III or IV ovarian cancer, had received surgery and chemotherapy, and self-reported they 
had received paclitaxel chemotherapy in the past. Slightly more than half (62%; n=8) 
had received paclitaxel chemotherapy in the past (rather than currently) with a mean of 
2.1 years since their last paclitaxel treatment. Commonly reported treatments received 
(in addition to paclitaxel) included carboplatin (67%; n=10), bevacizumab (20%; n=3), 
gemcitabine (13%; n=2), and doxorubicin (13%; n=2). Other commonly self-reported 
comorbid conditions among the women included hypertension (40%; n=6), osteoarthritis 
or degenerative arthritis (33%; n=5), and back pain (40%; n=6).  
TIMP Symptom Experience 
Intensity. Table 3-2 displays mean BPI TIMP intensity ratings at their worst and 
least, on average, and “now” as well as for the total score and diary pain ratings. Using 
established cutpoints for mild, moderate, and severe pain and BPI pain ratings, over half 
of women reported their average TIMP as moderate or severe (53%). Using established 
cutpoints for mild, moderate, and severe pain and morning, nighttime, and combined diary 
pain ratings, most women reported TIMP as mild (83%, 58%, and 64%, respectively). The 
proportion of women who had moderate or severe pain on the BPI total score was higher 
(46%) than the proportion of women who had moderate or severe pain on the combined 
diary (36%). 
Distress. The mean distress level reported by women was 4.7 (Mdn=5, mode=5, 
SD=2.4, and range: 0-8). Using reported distress levels and the established cutpoints for 
mild, moderate, and severe pain, women were grouped into phenotypes. Most (40%; n=6) 
women reported their TIMP was a variable mix of distress and intensity (i.e., ratings were 
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in mild [0 to 4] to severe [7 to 10] range). Other phenotypes included: mild, where all 
ratings were in the mild range (0 to 4) (27%; n=4); mild to moderate, where all ratings 
were in mild (0 to 4) or moderate range (5 to 6) (20%; n=3); moderate to severe, where all 
ratings were in moderate (5 to 6) or severe range (7 to 10) (7%; n=1); and severe, where 
all ratings were in severe range (7 to 10) (7%; n=1).  
Duration. For the 11 women completing pain diaries, nearly half (45%, n=5) 
reported their duration of pain was 100% (i.e., TIMP was present at an intensity level > 1 
at all recorded time points) of the time, 36% (n=4) reported their duration of pain was at 
least 70% of the time (but not constant), and 18% (n=2) reported their duration of pain was 
less than 50% of the time.  
Furthermore, summarizing across intensity, distress, and duration, over a quarter 
(27%) of women reported TIMP that was moderate to severe in intensity on average, 
constant (i.e., pain was > 1 at all recorded time points), and moderate to severely 
distressing. Other phenotype patterns were reported among the women and varied 
considerably.  
Location. The proportion of women who endorsed pain in each of the 8 sections is 
shown in Table 3-3. The mean total number of areas endorsed by women was 3.7 
(Mdn=3.5, mode=2 and 4, SD=2.1, and range: 1-8). Pain was most often situated in the 
lower extremities followed by the upper extremities). Most (79%; n=11) women identified 
TIMP as present in 2 to 5 of the locations on the body diagram.  
Quality. The proportion of women who endorsed each of the 15 TIMP descriptors 
is shown in Table 3-4. “Aching” was endorsed most (93%; n=11) by the women. 
“Throbbing,” “nagging,” “miserable,” and “tender” were the other top 5 descriptors. The 
mean total number of descriptors endorsed by women was 8.3 (Mdn=9, mode=9, SD=3.3, 
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and range: 4-15). Most (75%; n=9) women reported more than 5 descriptors 
characterizing the quality of their TIMP.  
Temporal Pattern. Morning, nighttime, and combined TIMP intensities over 28 
days were graphed and analyzed. There was considerable individual variability in TIMP 
over time both within and across individuals. No clear temporal pattern emerged across all 
individuals. See Figure 3-2. 
Aggravating/alleviating Factors. The average amount of pain relief in the last 
week provided by pain treatments or medications was 46% (Mdn=45%, Mode=50%, 
SD=25.3, and range: 0-100). Open-ended responses to the question of what makes the 
pain better included: rest (60%; n=9); medications both oral and topical (53%; n=8), and 
heat (47%; n=7). Including rest, medications, and heat, women reported a total of 6 
different types of alleviating factors (M=1.9, Mdn=2.0, Mode=1.0, SD=1.0, and range: 1-4). 
Open-ended responses to the question of what makes the pain worse included: walking 
(50%; n=7); standing (21%; n=3), lifting or bending (21%, n=3), and sitting or lying for too 
long (21%; n=3). Including walking, standing, lifting or bending, and sitting or lying for too 
long, women reported a total of 9 different types of aggravating factors (M=1.5, Mdn=1.0, 
Mode=1.0, SD=0.74, and range: 0-3). When asked, women most frequently reported using 
warm compresses (67%; n=10), relaxation techniques (53%; n=8), and distraction (33%; 
n= 5) as alternative methods for pain relief. Massage was entered by the only participant 
who endorsed “other.” 
Pain Management. Most (67%; n=10) women reported taking pain medicine only 
when necessary and most (54%; n=7) did not take pain medicine every day. The sample 
was almost evenly split between women who did not feel they required a stronger type of 
pain medication (57%; n=8) and those that did (43%; n=6). Women taking pain medication 
for treatment of TIMP most frequently reported that it took 1 hour (20%; n=3) or 4 hours 
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(20%; n=3) before pain returned; however, most (71%; n=10) women did not feel they 
needed to take more pain medication than was prescribed by their doctor and none of the 
women were concerned they were using too much pain medication. Only two women 
reported having side effects from their pain medication (14%) and these included: 
constipation, somnolence, and pruritus. Most (93%; n=13) women reported they did not 
feel they required further information about their pain medication. When asked about 
medications not prescribed by a doctor but taken to help relieve pain, women reported 
using nonsteroidal anti-inflammatory agents such as acetaminophen, 
aspirin/paracetamol/caffeine, ibuprofen, and naproxen to help relieve their pain.  
Co-occurring Symptoms 
Descriptive statistics including mean scores and range of scores for other symptom 
measures are shown in Table 3-5. Since a PROMIS symptom score ≥ 55 is indicative of a 
clinically relevant symptom,52 the median scores suggest that the majority of patients also 
had substantial pain interference, fatigue, and sleep problems. Spearman’s correlations 
are shown in Table 3-6. Greater TIMP intensity or distress was associated with greater 
intensity and interference of co-occurring symptoms. The exception was hot flash 
interference and morning, nighttime, and combined pain diary intensity ratings. Greater 
pain diary intensity was related to less hot flash interference. Additionally, with the 
exception of sleep disturbance, the strength of most correlations was medium to large. In 
general, the diary intensity ratings did not correlate as strongly as the BPI did with co-
occurring symptoms. 
Discussion 
The results of this pilot study provide new findings of the multi-dimensional 
description of TIMP in women with ovarian cancer. In this small sample, there was a 
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great deal of variability in individual’s experiences of TIMP. The most common TIMP 
intensity and distress phenotypes which emerged among the women in our study were 
those with a variable mix for intensity and distress from TIMP and those with mildly 
intense and mildly distressing TIMP. However, 27% had a more severe phenotype with 
constant TIMP that was moderately to severely intense and distressing. There was also 
considerable individual variability in TIMP over time both within and across individuals with 
no clear temporal patterns in TIMP. Second, most women experienced pain at multiple 
body sites, indicating the more diffuse rather than localized nature of TIMP. Furthermore, 
TIMP’s intensity, near constant duration, aching nature, diffuse location in the body, 
variable temporal pattern, and fact that everyday functions such as walking and sitting 
were aggravating factors indicate a similarity between TIMP and other types of chronic 
musculoskeletal pain (i.e., osteoarthritis) and suggest TIMP may negatively impact 
functioning. The latter is supported by high PROMIS interference scores. These findings 
illustrate the importance of addressing TIMP in clinical practice and in future research.  
Similar to previous clinical reports of TIMP, pain medications were often insufficient 
to fully alleviate TIMP, another analogy with chronic pain. Recommendations for 
management of chronic pain consider a multi-faceted approach to achieve therapeutic 
goals. While pharmacotherapy is an important component of chronic pain management, 
alternative therapies such as exercise, yoga, acupuncture, and massage play a 
complementary role.53 These attributes of and recommendations regarding chronic pain 
management may provide direction for future studies evaluating the role of complementary 
pain management therapies in addition to pharmacotherapy for better TIMP management. 
Prior studies have been limited in describing TIMP, focusing principally on pain 
intensity9 rather than a broader range of dimensions such as distress, duration, location, 
quality, temporal pattern, aggravating and alleviating factors, and pain management. 
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Moreover, even the studies evaluating pain intensity10, 16-20 have used common oncology 
toxicity grading scales which are limited in two ways. First, toxicity scales are typically 
four points and therefore, do not allow comparison to standard 11-point numeric pain 
rating scales. Second, toxicity scales are unidimensional and do not capture distress, 
duration, temporal pattern, and other important aspects of a symptom. As such, our 
study findings provide a more detailed description of TIMP that is useful for assessing 
and managing this type of treatment-related pain. In addition, our study findings may 
serve as a benchmark or comparison for future TIMP studies.   
The few studies that have assessed TIMP distress, quality, and temporal pattern 
provide some comparison for our findings. Boehmke & Dickerson12 described distress 
and quality of “bone pain” following paclitaxel chemotherapy in women with breast 
cancer. In this qualitative study, distress was described as “severely affecting” the 
women and pain quality was described as severe and “jabbing.” Pusztai et al.20 identified 
the temporal pattern of “muscle aches” increased following paclitaxel chemotherapy, 
peaked between days 3 to 5, and resolved by the end of the cycle. Although these 
findings present a potential temporal pattern of TIMP in those who are actively receiving 
treatment with paclitaxel-containing regimens, our study supports that TIMP may be 
present well beyond completion of paclitaxel chemotherapy. In our study, women who 
were off paclitaxel for an average of two or more years continued to report TIMP. 
Findings from our study also suggest that, although there are few studies 
describing TIMP, TIMP may mimic pain that is analogous to the pain experienced in 
osteoarthritis. Qualitative work describing osteoarthritic pain54 reveals its complex nature 
which is not adequately assessed by intensity ratings alone. Additionally, this pain is 
described as numerous and differing in intensity, duration, depth, type of occurrence, 
impact, and rhythm as well as in painful sensations and associated symptoms; 
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furthermore, this pain is described as being worsened by physical activity including the 
activities required for everyday functioning.54 Our study findings add to the literature by 
further describing TIMP and supporting the need for further research which should 
include prospective, longitudinal studies describing TIMP and its variability with the 
addition of a non-cancer control group with chronic musculoskeletal pain (i.e., 
osteoarthritis) to establish common patterns and any differences. 
Our pilot findings also suggest TIMP, like other cancer treatment-related 
symptoms, may occur within a symptom cluster of general pain, peripheral neuropathy, 
sleep disturbance, anxiety, depression, fatigue, and hot flashes. Our results revealed a 
paradoxical finding with worse hot flash interference associated with worse pain when 
using the BPI pain ratings, but less hot flash interference was associated with worse 
pain when using the diary pain ratings. This may be a chance finding due to our small 
pilot sample (with even less reporting hot flashes) or it may be in some way attributable 
to the cross-sectional vs. longitudinal difference in the pain measures. However, our 
findings are otherwise consistent with the symptom science literature supporting patients 
with chronic conditions such as cancer experience an array of multiple co-occurring 
symptoms.26 In the latest expert panel proceedings and recommendations on advancing 
symptom science through symptom cluster research, two of the three most common 
symptom clusters identified were: (1) fatigue, pain, depression, and sleep disturbance; 
and (2) anxiety and depression. These clusters were identified from studies mostly 
involving cancer patients.26 Similarly, sleep disturbance, pain, anxiety, depression and 
fatigue are five of the most prevalent, chronic, disabling, and under-treated symptoms in 
both the general population and in clinical practice.52 In a sample of Veteran patients 
with chronic musculoskeletal pain, Davis et al.52 identified that sleep disturbance, pain, 
anxiety, depression, and fatigue commonly cluster with the norm being a 
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polysymptomatic patient, whereas only about 1 in 10 patients were monosymptomatic. 
Collectively, these studies, in cancer and chronic musculoskeletal pain, support the 
preliminary relationships between TIMP intensity and distress and other co-occurring 
symptoms that were identified by our study. Although Davis et al.52 provided preliminary 
evidence in support for the calculation of a composite (i.e., sleep disturbance, pain, 
anxiety, depression, and fatigue) symptom score derived from PROMIS measures that 
could be used clinically to address multiple co-occurring symptoms, further evidence on 
how to optimally assess and manage co-occurring symptoms or symptom clusters in 
clinical practice requires further research. 
Our study had several strengths including being the first study to attempt to 
describe multiple dimensions of TIMP in a sample of women with ovarian cancer. Before 
now, details such as intensity, distress, duration, location, quality, temporal pattern, 
aggravating and alleviating factors, and pain management have been unspecified in the 
literature. Our study also provides new understanding of how TIMP intensity and distress 
are associated with co-occurring symptoms in women with ovarian cancer who were 
being or had been treated with paclitaxel chemotherapy.  
Study findings should be interpreted in the context of some study limitations. 
First, because this was a small pilot study, we recommend replication in a larger sample. 
Also, because of the small pilot sample, we were unable to control for potential 
confounding influences in the analyses. Second, the study focused on women with 
ovarian cancer to better understand this particular patient population, but this limits 
generalizability to other cancers. Third, comorbid conditions such as osteoarthritis or 
degenerative arthritis, or back pain, which were present in our sample of women, may 
have impacted our ability to distinguish TIMP from these chronic pain conditions. 
Although we asked patients to answer TIMP-related questionnaires in thinking about 
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their TIMP, it is unknown whether all women were able to delineate this difference as 
instructed. Future prospective, longitudinal studies comparing chronic musculoskeletal 
pain with TIMP will delineate differences between these conditions. Fourth, although the 
term TIMP suggests musculoskeletal pain caused by taxane chemotherapy agents, our 
study did not attempt to identify causation. Rather, we only intended to describe muscle 
and/or joint pain reported by women following paclitaxel (assumed to be TIMP) and the 
associations between this type of pain and other co-occurring symptoms. Finally, 
differences between women who were actively undergoing treatment and those who had 
been treated in the past were not compared within the context of our study’s findings; 
furthermore, this treatment information (nor demographic information) was not verified 
against medical records.  
Implications for Nursing 
Oncology nurses play an important role in managing distressing symptoms and 
nurses should continue to assess this symptom in a multi-dimensional context (as is 
recommended for initial descriptions of pain) to better intervene on aggravating and 
alleviating factors and pain management regimens. One important finding from this pilot 
study was that the TIMP pain diary did not perform as well as the standardized 
questionnaires and therefore, nurses should use caution when recommending patients 
keep a TIMP pain diary at home. Pain diaries may not be as helpful in assessing and 
managing TIMP because of the constant (i.e., chronic) nature of TIMP pain, which was 
identified in our study. Additionally, TIMP diaries may only provide useful information in 
populations of women who are on active treatment vs. women who have been treated 
with paclitaxel chemotherapy in the past, as was the majority of women who participated 
in our study. Finally, associations between TIMP intensity and distress and co-occurring 
symptoms are likely and nurses should assess for and include these relationships in 
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clinical care and in future research on symptom clusters specific to ovarian cancer 
survivors. 
Conclusion 
 Among women with stage III to IV ovarian cancer who were being or had been 
treated with paclitaxel-containing regimens, TIMP is moderate to severe in intensity on 
average for most women and is moderately distressing. TIMP intensity and distress are 
also associated with co-occurring symptoms including general pain, peripheral 
neuropathy, sleep disturbance, anxiety, depression, fatigue, and hot flashes. 
Multidimensional, comprehensive descriptions of the TIMP symptom experience and the 
associations between TIMP intensity and distress and co-occurring symptoms should be 
replicated in studies with larger sample sizes. A prospective, longitudinal study with a 
comparison group of non-cancer women with chronic musculoskeletal pain would 
provide additional details about the TIMP symptom experience and its variability and 
could improve management of this symptom in ovarian cancer survivors. 
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Figure 3-1 
Study Accrual Flow Diagram   
 
 
 
Note. TIMP= Taxane-induced musculoskeletal pain  
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Figure 3-2 
Patterns Endorsed by Participants to Describe Temporality of TIMP (N=11)  
 
Figure 3-2a: Temporal Patterns for Morning TIMP 
 
  
0
2
4
6
8
10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Morning Pain
Participant 2 Participant 3 Participant 33 Participant 51
Participant 61 Participant 62 Participant 64 Participant 71
Participant 75 Participant 78 Participant 79
 84 
 
Figure 3-2b: Temporal Patterns for Nighttime TIMP 
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Figure 3-2c: Temporal Patterns for Combined TIMP 
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Table 3-1 
Sample Demographic and Treatment Characteristics (N=15) 
 % (n) 
Race and Ethnicity 
Black or African American, Not Hispanic or Latino 
White or Caucasian, Not Hispanic or Latino 
More than one race 
 
6.7% (1) 
86.7% (13) 
6.7% (1) 
Marital Status 
Single 
Married or partnered 
Widowed 
 
13.3% (2) 
 
73.3% (11) 
 
13.3% (2) 
Employment  
Full-time 
Unemployed 
Retired 
Other 
 
20.0% (3) 
13.3% (2) 
40.0% (6) 
26.7% (4) 
Education 
Some high school  
High school degree 
Some undergraduate 
Undergraduate degree 
 
20.0% (3) 
26.7% (4) 
46.7% (7) 
6.7% (1)  
Stage of Cancer 
I 
II 
 
0% (0) 
6.7% (1) 
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III 
IV 
73.3% (11) 
20.0% (3) 
Treatment 
Surgery and chemotherapy 
Surgery, radiation, and chemotherapy 
 
93% (14) 
 
7% (1) 
Treatment 
Actively receiving paclitaxel 
Treated with paclitaxel in the past 
 
20% (3) 
 
80% (12) 
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Table 3-2 
Descriptive Statistics for TIMP Pain Intensity Questionnaire and Diary 
 Mean Median Mode(s) SD Range % 
mild 
% 
moderate 
% 
severe 
BPI Ratings1         
Worst 5.8 7 3, 8 2.4 2-9 33% 13% 53% 
Least 2.6 2 3 2.3 0-7 80% 7% 13% 
Average 4.3 5 3, 5 2.3 1-8 47% 33% 20% 
Now 4.1 4 3,6 2.6 0-8 60% 20% 20% 
Total 4.2 4 2 2.0 2-8 53% 33% 13% 
Diary 
Ratings2 
        
Morning 2.7 3 3 2.0 0-8 83% 14% 3% 
Nighttime 3.9 4 2 2.7 0-10 58% 20% 22% 
Combined 3.3 3.5 0 2.2 0-8 64% 27% 9% 
Note. BPI= Brief Pain Inventory; SD= standard deviation 
1n=15 
2n=11 
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Table 3-3 
Body Locations where TIMP was Experienced by Participants (N=14) 
 % (n) 
Left hip, thigh, knee, leg, ankle, foot 93% (13) 
Right hip, thigh, knee, leg, ankle, foot 79% (11) 
Posterior head and neck 50% (7) 
Left shoulder arm, elbow, wrist, hand 50% (7) 
Right shoulder, arm, elbow, wrist, hand 43% (6) 
Posterior thorax 29% (4) 
Anterior thorax 21% (3) 
Anterior head and neck 14% (2) 
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Table 3-4  
Descriptors Endorsed by Participants to Describe TIMP Quality (N=12)  
 % (n) 
Aching 92% (11) 
Throbbing 75% (9) 
Nagging 75% (9) 
Miserable 75% (9) 
Tender 67% (8) 
Exhausting 58% (7) 
Tiring 58% (7) 
Penetrating 58% (7) 
Gnawing 50% (6) 
Sharp 50% (6) 
Shooting 42% (5) 
Stabbing 33% (4) 
Burning 33% (4) 
Numb 33% (4) 
Unbearable 25% (3) 
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Table 3-5 
Descriptive Statistics for Other Symptom Measures 
 Mean Median Mode(s) SD Range 
Measure      
PROMIS – Pain Interference (General)1 59.9 60.3 64 6.2 49-69 
NPS-CIN2 12.5 11.0 9, 10 4.8 6-24 
PROMIS- Sleep Disturbance1 57.9 58.2 52  6.1 47-72 
PROMIS- Fatigue1 58.9 60.8 63 7.8 41-69 
PROMIS- Anxiety1 53.2 52.8 37 10.8 37-68 
PROMIS- Depression1 50.4 50.8 38 10.4 38-66 
HFRDIS3 29.1 15 N/A 32.8 0-82 
Note. SD= standard deviation: PROMIS= Patient-reported Outcomes Measurement 
Information System; NPS-CIN = Neuropathy Pain Score (Chemotherapy-Induced 
Neuropathy-Specific); HFRDIS = Hot Flash Related Daily Interference Scale; N/A= not 
applicable 
1n=15 
2n=14 
3n=7 reported hot flashes 
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Table 3-6 
Spearman Correlations between TIMP Intensity and Distress and Other Symptoms 
  PROMIS – 
Pain 
Interference 
(General) 
NPS-
CIN 
PROMIS- 
Sleep 
Disturbance  
PROMIS- 
Fatigue 
PROMIS- 
Anxiety 
PROMIS- 
Depression 
HFRDIS1 
BPI 
Intensity 
       
 Worst .45 .29 .17 .45 .33 .23 .32 
Least .69** .49 .20 .70** .72** .64* .42 
Average .80** .65* .28 .67** .61* .52* .47 
Now .63* .41 .29 .37 .33 .34 .18 
Total .74** .51 .25 .62* .54* .50 .39 
Diary 
Intensity 
       
Morning  .22 .49 .27 .61* .51 .19 -.80 
Nighttime  .30 .54 .19 .66* .50 .20 -.80 
Combined  .27 .54 .22 .64* .49 .15 -.80 
BPI 
Distress 
.74** .45 .32 .47 .50 .54* .29 
Note. BPI= Brief Pain Inventory; TIMP= Taxane-induced musculoskeletal pain; 
PROMIS= Patient-reported Outcomes Measurement Information System; NPS-CIN = 
Neuropathy Pain Score (Chemotherapy-Induced Neuropathy-Specific); HFRDIS = Hot 
Flash Related Daily Interference Scale; * = correlation is significant at the 0.05 level; ** = 
correlation is significant at the 0.01 level 
 
1n=7 reported hot flashes 
 93 
References 
 
1.  American Cancer Society (ACS). Cancer Facts and Figures 2016. Atlanta, GA: 
American Cancer Society; 2016. 
2.  National Cancer Institute (NCI). SEER Stat Fact Sheets: Ovarian Cancer. 2016. 
Available from: https://seer.cancer.gov/statfacts/html/ovary.html.  
3.  Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: What is 
it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624-
631. 
4.  Davis LL, Carpenter JS. A systematic review of nonpharmacologic interventions 
for treatment-related symptoms in women with ovarian cancer. Clin J Oncol Nurs. 
Oct 2015;19(5):535-542. 
5.  Grunewald T, Ledermann JA. Targeted Therapies for Ovarian Cancer. Best Pract 
Res Clin Obstet Gynaecol. 2016. [Epub ahead of print]. 
6.  Havrilesky LJ, Alvarez Secord A, Ehrisman, JA, et al. Patient preferences in 
advanced or recurrent ovarian cancer. Cancer. 2014;120(23):3651-3659.  
7.  Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: Evidence 
for a core set of cancer-related and treatment-related symptoms from the Eastern 
Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. 
Cancer. 2013;119(24):4333-4340.  
8.  Yarbro CH, Wujcik D, Gobel BH. Cancer Symptom Management (4th ed.). 
Burlington, MA: Jones and Bartlett Learning; 2014. 
9.  Davis LL, Carpenter JS, Otte JL. State of the Science: Taxane-Induced 
Musculoskeletal Pain. Cancer Nurs. May-Jun 2016;39(3):187-196. 
 94 
10.  Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-
2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in 
early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21(14):2645-2650.  
11.  Boccardo F, Amadori D, Guglielmini P, et al. Epirubicin followed by 
cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by 
epirubicin and vinorelbine in patients with high-risk operable breast cancer. 
Oncology. 2010;78(3-4):274-281.  
12.  Boehmke MM, Dickerson SS. Symptom, symptom experiences, and symptom 
distress encountered by women with breast cancer undergoing current treatment 
modalities. Cancer Nurs. 2005;28(5):382-389.  
13.  Bulent Akinci M, Algin E, Inal A, et al. Sequential adjuvant docetaxel and 
anthracycline chemotherapy for node positive breast cancers: a retrospective 
study. J BUON. 2013;18(2):314-320.  
14.  Gallardo-Rincon D, Perez-Landeros L, Onate-Ocana LF, et al. Long-term results 
of paclitaxel in FIGO stage III ovarian carcinoma. Anticancer Drugs. 
2003;14(5):347-352.  
15.  Gatzemeier U, Jagos U, Kaukel E, Koschel G, von Pawel J. Paclitaxel, carboplatin, 
and oral etoposide: a phase II trial in limited-stage small cell lung cancer. Semin 
Oncol. 1997;24(4 Suppl 12):S12-149-152. 
16.  Kaklamani VG, Siziopikou K, Scholtens D, et al. Pilot neoadjuvant trial in HER2 
positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast 
Cancer Res Treat. 2012;132(3):833-842.  
 95 
17.  Kurtz JE, Kaminsky MC, Floquet A, et al. Ovarian cancer in elderly patients: 
carboplatin and pegylated liposomal doxorubicin versus carboplatin and 
paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO 
sub-study. Ann Oncol. 2011;22(11):2417-2423.  
18.  O'Brien ME, Splinter T, Smit EF, et al. Carboplatin and paclitaxol (Taxol) as an 
induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell 
lung cancer. an EORTC phase II study (EORTC 08958). Eur J Cancer. 
2003;39(10):1416-1422.  
19.  Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before 
surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology 
Team. J Thorac Cardiovasc Surg. 2000;119(3):429-439.  
20.  Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of 
inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 
2004;25(3):94-102.  
21.  Trope C, Kaern J, Kristensen G, Rosenberg P, Sorbe B. Paclitaxel in untreated 
FIGO stage III suboptimally resected ovarian cancer. Ann Oncol. 1997;8(8):803-
806. 
22.  Grimmer-Somers K, Vipond N, Kumar S, Hall G. A review and critique of 
assessment instruments for patients with persistent pain. J Pain Res. 2009;2:21-
47.  
23.  Aktas A. Cancer symptom clusters: current concepts and controversies. Curr 
Opin Support Palliat Care. 2013;7(1):38-44.  
 96 
24.  Barsevick A. Defining the Symptom Cluster: How Far Have We Come? Semin 
Oncol Nurs. 2016;32(4):334-350.  
25.  Barsevick A, Aktas A. Cancer symptom cluster research: new perspectives and 
tools. Curr Opin Support Palliat Care. 2013;7(1):36-37.  
26.  Miaskowski C, Barsevick A, Berger A, et al. Advancing Symptom Science 
Through Symptom Cluster Research: Expert Panel Proceedings and 
Recommendations. J Natl Cancer Inst. 2017;109(4):1-9.  
27.  Oh H, Seo Y, Jeong H, Seo W. The identification of multiple symptom clusters 
and their effects on functional performance in cancer patients. J Clin Nurs. 
2012;21(19-20):2832-2842.  
28.  Thomas BC, Waller A, Malhi RL, et al. A longitudinal analysis of symptom 
clusters in cancer patients and their sociodemographic predictors. J Pain 
Symptom Manage. 2014;47(3):566-578.  
29.  Wood LJ, Weymann K. Inflammation and neural signaling: etiologic mechanisms 
of the cancer treatment-related symptom cluster. Curr Opin Support Palliat Care. 
2013;7(1):54-59.  
30.  Donovan HS, Hartenbach EM, Method MW. Patient–provider communication and 
perceived control for women experiencing multiple symptoms associated with 
ovarian cancer. Gynecol Oncol. 2005;99(2):404-411.  
31.  Ferrell B, Smith S, Cullinane C, Melancon C. Symptom Concerns of Women with 
Ovarian Cancer. J Pain Symptom Manage. 2003;25(6):528-538.  
32.  Holzner B, Kemmler G, Meraner V, et al. Fatigue in ovarian carcinoma patients: a 
neglected issue? Cancer. 2003;97(6):1564-1572. 
 97 
33.  Wagner LI, Schink J, Bass M, et al. Bringing PROMIS to practice: brief and 
precise symptom screening in ambulatory cancer care. Cancer. 2015;121(6):927-
934.  
34.  National Cancer Institute (NCI). Cancer Drug Information: Paclitaxel. 2013. 
Available from: http://www.cancer.gov/cancertopics/druginfo/paclitaxel.  
35.  Choi MR, Solid CA, Chia VM, et al. Granulocyte colony-stimulating factor (G-
CSF) patterns of use in cancer patients receiving myelosuppressive 
chemotherapy. Support Care Cancer. 2014;22(6):1619-1628.  
36.  Henry NL, Pchejetski D, A'Hern R, et al. Inflammatory cytokines and aromatase 
inhibitor-associated musculoskeletal syndrome: a case-control study. Br J 
Cancer. 2010;103(3):291-296.  
37.  Matsui K, Mori T, Sawada M, et al. Evaluation of primary prophylaxis with 
granulocyte colony-stimulating factor for epithelial ovarian cancer. Eur J 
Gynaecol Oncol. 2014;35(1):48-51.  
38.  Ozols RF, Bundy BN, Greer BE, et al. Phase III Trial of Carboplatin and 
Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally 
Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin 
Oncol. 2003;21(17):3194-3200.  
39.  Singer O, Cigler T, Moore AB, et al. Hypovitaminosis D is a predictor of 
aromatase inhibitor musculoskeletal symptoms. Breast J. 2014;20(2):174-179.  
40.  Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant 
treatment of breast cancer. N Engl J Med. 2008;358(16):1663-1671.  
 98 
41.  Rare Patient Voice, LLC (RPV). Rare Patient Voice, LLC: Helping Patients with 
Rare Diseases Voice their Opinions. 2017. Available from: 
https://www.rarepatientvoice.com/.  
42.  Indiana Clinical and Translational Sciences Institute (ICTSI). Research and 
Collaboration Tools. 2016. Available from: 
https://www.indianactsi.org/research/collaboration-
tools?highlight=WyJyZWRjYXAiLCIncmVkY2FwIl0=.  
43.  Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered 
Comorbidity Questionnaire: a new method to assess comorbidity for clinical and 
health services research. Arthritis Rheum. 2003;49(2):156-163.  
44.  University of Texas MD Anderson Cancer Center. The Brief Pain Inventory (BPI). 
2017. Available from: http://www.mdanderson.org/education-and-
research/departments-programs-and-labs/departments-and-divisions/symptom-
research/symptom-assessment-tools/brief-pain-inventory.html.  
45.  Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain 
clinical trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19.  
46.  Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement 
Information System (PROMIS) developed and tested its first wave of adult self-
reported health outcome item banks: 2005-2008. J Clin Epidemiol. 
2010;63(11):1179-1194.  
47.  Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified 
total neuropathy score-reduced and neuropathic pain severity items when used 
to measure chemotherapy-induced peripheral neuropathy in patients receiving 
taxanes and platinums. Cancer Nurs. 2010;33(3):173-183.  
 99 
48.  Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for 
assessing the impact of hot flashes on quality of life following breast cancer. J 
Pain Symptom Manage. 2001;22(6):979-989.  
49.  Carpenter JS, Guthrie KA, Larson JC, et al. Effect of escitalopram on hot flash 
interference: a randomized, controlled trial. Fertil Steril. 2012;97(6):1399-1404.  
50.  Pallant J. SPSS Survival Manual: A Step by Step Guide to Data Analysis using 
IBM SPSS (6th ed.). New York, NY: McGraw Hill Education; 2016. 
51.  Kapstad H, Hanestad BR, Langeland N, Rustoen T, Stavem K. Cutpoints for 
mild, moderate and severe pain in patients with osteoarthritis of the hip or knee 
ready for joint replacement surgery. BMC Musculoskelet Disord. 2008;9:55.  
52.  Davis LL, Kroenke K, Monahan P, Kean J, Stump TE. The SPADE Symptom 
Cluster in Primary Care Patients With Chronic Pain. Clin J Pain. 2016;32(5):388-
393.  
53.  Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Physical 
Therapy Treatments for Chronic Non-Cancer Pain: A Review of Guidelines. 
CADTH Rapid Response Reports. 2016;Nov:1-33. 
54.  Cedraschi C, Delezay S, Marty M, et al. “Let’s Talk about OA Pain”: A Qualitative 
Analysis of the Perceptions of People Suffering from OA. Toawards the 
Deveopment of a Specific Pain OA-Related Questionnaire, the Osteoarthritis 
Symptom Inventory Scale (OASIS). PLoS One. 2013;8(11):e79988.  
 
  
 100 
CHAPTER 4 
This chapter presents results from the dissertation research study “Taxane-
induced Musculoskeletal Pain in Women with Ovarian Cancer,” and presents the 
associations between TIMP and patient-reported outcomes. 
Ovarian cancer has the highest mortality of all gynecological cancers, due in 
large part to the often asymptomatic presentation of women during the early stages of 
the disease.1, 2 As a result, over 60% of women are diagnosed at an advanced stage.1, 2 
3 After initial surgery and chemotherapy, disease recurrence occurs in most women and, 
thus, most women experience life with active disease requiring ongoing treatment.3-5 
These facts about women with ovarian cancer bring discussions about health-related 
quality of life to the forefront in clinical practice.6 
In research, health-related quality of life generally consists of an individual’s 
physical functioning and emotional, social, and psychological well-being. Measures of 
health-related quality of life typically evaluate the extent to which an individual’s disease 
and/or treatment affect these important dimensions.2, 7, 8 Symptom burden is an 
important variable impacting health-related quality of life.2, 9  Treatment-related 
symptoms such as taxane-induced musculoskeletal pain (TIMP) (i.e., pain including 
myalgia and/or arthralgia and affecting more than half of patients treated with taxane-
based chemotherapy) are likely to impact health-related quality of life of ovarian cancer 
survivors. Attention to TIMP and the impact of TIMP on patient-reported outcomes is 
especially important in ovarian cancer survivors where inclusion of patient-reported 
outcomes is an important endpoint, in clinical trials and in discussions with healthcare 
providers about therapy options and plans of care.8, 10 
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Background of the Problem 
TIMP is likely to be associated with patient-reported outcomes including greater 
interference with daily activities, poorer physical functioning, and lower health-related 
quality of life. Although research to date has not identified TIMP to be a dose-limiting 
toxicity, the myalgia and/or arthralgia experienced by patients receiving taxane-based 
chemotherapy can result in impaired mobility, secondary to the limitation of joint function, 
and the experience of pain can affect physical functioning.11 Though it has not been widely 
studied, TIMP very likely undermines cancer survivors’ health-related quality of life in ways 
that are similar to the burden of persistent musculoskeletal pain seen in non-oncology 
populations.  
Data from non-oncology populations suggest the following facts about pain. Pain is 
among the most common reasons for temporary and permanent work disability.12, 13 The 
World Health Organization recognizes the significant contribution of musculoskeletal 
conditions to the global burden of disease.14 Additionally, the Institute of Medicine (IOM) 
has highlighted the significant functional and economic effects of musculoskeletal pain.15 
Musculoskeletal pain is the most common, disabling, and costly of all pain complaints.13 
Pain is known to be even more prevalent in individuals with psychiatric comorbidity, 
specifically mood disorders, and is a strong predictor of both onset and persistence of 
depression; likewise, depression is a strong predictor of pain.16 Furthermore, the 
comorbidity of pain and chronic conditions, such as impaired sleep and emotional distress, 
decrease an individual’s active coping in addition to negatively impacting health-related 
quality of life, disability, and even response to treatment.16, 17 These facts suggest TIMP is 
likely negatively associated with patient-reported outcomes. However, because it has not 
been comprehensively studied, the strength, direction, and significance of associations 
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between TIMP and interference with daily activities, physical functioning, and health-
related quality of life are currently unknown and unspecified in the literature.  
Therefore, the purpose of this paper was to identify associations between TIMP 
(intensity and distress) and patient-reported outcomes (i.e., interference with daily 
activities, physical functioning, and health-related quality of life) in women with ovarian 
cancer who were being or had been treated with paclitaxel-containing regimens. 
Methods 
Design, Setting, and Participants 
This was a cross-sectional, descriptive, correlational pilot study describing TIMP 
in women with ovarian cancer. Participants were a convenience sample of women with 
ovarian cancer who were recruited from an outpatient cancer clinic in the Midwest, local 
cancer support communities, and a national cancer survivors’ research registry between 
December 1, 2015 and October 14, 2016. Inclusion criteria for participation in our study 
are described in full detail in Chapter 3 of the dissertation. 
Data Collection 
The study was approved by the Scientific Review Committee and Institutional 
Review Board. Details regarding the procedures for data collection are fully described in 
Chapter 3.  
Measures 
Participants completed questionnaires and a 28-day TIMP Pain Diary.  
Demographic and treatment information were self-reported and were not verified 
against medical records. All collected demographic and treatment variables are reported 
in full detail in the text and tables of Chapter 3. Additionally, comorbidities were evaluated 
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using the 12-item validated Self-Administered Comorbidity Questionnaire (SCQ) modified. 
Cronbach’s alpha, including among cancer patients, was 0.94.18 
TIMP Intensity and Distress 
TIMP intensity was assessed using the 32-item validated Brief Pain Inventory – 
Long Form (BPI) and a standard 28-day TIMP symptom reporting diary. Cronbach’s 
alpha for the BPI – Long Form has ranged from 0.77 to 0.91.19 On the BPI, participants 
rated worst, least, average, and current (now) pain intensity. On the TIMP Pain Diary, 
participants were asked to report the intensity of their morning and nighttime TIMP on a 
scale of 0 (not at all intense) to 10 (extremely intense). Those on active treatment were 
given a place to specify whether or not they had received treatment with paclitaxel 
chemotherapy on that day.  
TIMP distress was measured using a single item which asked participants to rate 
distress caused by TIMP on a 0-10 scale. Anchors were not at all distressing to 
extremely distressing.  
Patient-reported Outcomes 
Interference with daily activities. Interference with daily activities was evaluated 
with the seven BPI interference items. Participants rated how much TIMP interfered with 
seven daily activities including general activity, walking, work, mood, enjoyment of life, 
relations with others, and sleep. Response options were 0 (does not interfere) to 10 
(completely interferes). The interference score was calculated as the mean of the 
interference items.  Higher scores indicate worse interference with daily activities. 
Cronbach’s alphas, including among cancer patients, have ranged from 0.77 to 0.91.19 
Physical function. The Performance 10 (PF10) is a valid and reliable 10-item 
scale that is the physical functioning subscale of the MOS-SF-36, one of the most 
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commonly used measures of health-related quality of life.20, 21 The scale assesses the 
extent to which health limits physical activities. Higher scores reflect higher physical 
functioning. Cronbach’s alphas generally exceed 0.90.20, 21  
Health-related quality of life. Health-related quality of life was evaluated using 
the Functional Assessment of Cancer Therapy-General (FACT-G), which is a valid 28-item 
tool assessing physical well-being, social/family well-being, emotional well-being, and 
functional well-being. Item responses (0=not at all to 4=very much) yield total scores 
ranging from 0 to 112. Higher scores indicate higher quality of life. Cronbach’s alpha was 
0.89.22 
Data Analysis 
A description of the sample, including demographic and treatment information, 
was analyzed using descriptive statistics appropriate for the level of measurement. 
Missing data points for all of the analyses were handled by exclusion of cases pairwise.23 
TIMP Intensity and Distress 
BPI intensity ratings (analyzed as mean, median, mode, standard deviation, and 
range) and TIMP Pain Diary intensity ratings for morning, nighttime, and combined 
morning and nighttime pain (mean, median, mode, standard deviation, and range) for the 
28 days were analyzed. Also, all intensity ratings were examined in relation to BPI 
cutpoints24 of mild (0-4), moderate (5-6), and severe (7-10) pain. Distress was analyzed 
as mean, median, mode, standard deviation, and range. Commonly occurring phenotypes 
were established to group the women according to the severity of both the intensity and 
distress of their reported TIMP. Phenotypes were established by using the BPI intensity 
items and the distress item. Frequencies and percentages were analyzed for the 
phenotypes including mild, mild to moderate, moderate to severe, severe, and variable. 
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Patient-reported Outcomes 
Spearman’s correlations were used to measure relationships between TIMP 
(intensity and distress) and patient-reported outcomes (interference with daily activities, 
physical functioning, and health-related quality of life). Positive correlations indicated that 
greater TIMP intensity and/or distress was correlated with greater interference with daily 
activities, worse physical functioning, and/or worse health-related quality of life. The 
magnitude (r), direction (+/-), and significance (p value) of each relationship was analyzed 
and reported.  
Patient-reported outcomes measures were also described across each of the 
phenotypes (i.e., mild, mild to moderate, moderate to severe, severe, and variable). 
Descriptive statistics included mean, standard deviation, and range along with 95% 
confidence intervals across each of the outcome measures (interference with daily 
activities, physical functioning, and health-related quality of life).  
Results 
 Descriptive statistics describing the demographic and treatment characteristics of 
our sample are fully described in detail in Chapter 3 of the dissertation. The sample was 
comprised of women who were on average 56 years of age. Most were non-Hispanic, 
White, married or living with a partner, retired from work, and had completed some years 
toward an undergraduate degree. Most had a diagnosis of stage III or IV ovarian cancer, 
had received surgery and chemotherapy, and self-reported they received paclitaxel in 
the past with a mean of approximately 2 years since their last paclitaxel treatment. 
TIMP Intensity and Distress 
Table 4-1 shows BPI TIMP intensity ratings and distress ratings for each subject 
as well as the phenotype groupings. Most (40%; n=6) women described TIMP intensity 
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and distress as variable (i.e., ratings were in the mild [0 to 4] to severe [7 to 10] range). 
Other phenotypes included: mild, where all ratings were in the mild range (0 to 4) (27%; 
n=4); mild to moderate, where all ratings were in the mild (0 to 4) or moderate range (5 to 
6) (20%; n=3); moderate to severe, where all ratings were in the moderate (5 to 6) or 
severe range (7 to 10) (7%; n=1); and severe, where all ratings were in the severe range 
(7 to 10) (7%; n=1).  
Patient-reported Outcomes 
Spearman’s correlations are shown in Table 4-2. Greater TIMP intensity and 
distress was associated with greater interference with daily activities, worse physical 
functioning, and worse health-related quality of life. Across all outcomes, the strength of 
nearly all correlations was medium to large. In general, the diary intensity ratings did not 
correlate as strongly or as significantly as the BPI ratings with patient-reported outcomes. 
Patient-reported outcomes across phenotypes are shown in Table 4-3. This table 
also shows the pattern of greater TIMP intensity and distress being associated with 
greater interference with daily activities, worse physical functioning, and worse health-
related quality of life.  
Discussion 
 Two important findings are as follows. First, participant ratings and phenotypes 
showed large variability in TIMP intensity and distress. Second, greater TIMP intensity 
and distress were associated with worse patient-reported outcomes. This was true for 
the correlational matrix and when examining outcomes by phenotypes.   
 The first finding supports previous literature identifying large variability in reports 
of TIMP intensity and distress.25-36 Furthermore, the large variability in phenotypes for 
TIMP intensity and distress are consistent with two of the most recent systematic 
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reviews of TIMP37, 38 and other supporting literature which suggests TIMP is likely 
common39, 40 – affecting up to 94% of patients.37 Chiu et al38 identified percentages of 
taxane-induced arthralgia and myalgia ranged from 2.8% to 72%. Also, intensity appears 
to be dose dependent with doses of paclitaxel > 200mg/m2 leading to more frequent and 
intense TIMP.38, 41 Although dose of paclitaxel was not a variable assessed in this pilot 
study and comparisons between those women who were on active treatment and those 
women who were treated in the past were not made here due to the small sample size, 
this may have been a contributing factor to the large variation seen across phenotypes for 
TIMP intensity and distress. A prospective, longitudinal study (where differences in TIMP 
intensity and distress can be evaluated and compared across those on active treatment 
versus those who have received treatment with paclitaxel in the past but still report TIMP) 
seems to be the best recommendation for future research studies in order to better 
understand the seemingly variable and non-uniform nature of TIMP intensity and distress. 
The second finding is also consistent with other literature identifying greater pain 
intensity and distress are associated with worse patient-reported outcomes. The 
literature on chronic pain suggests pain is among the most common reasons for 
temporary and permanent work disability12, 13 and musculoskeletal pain, specifically, is the 
most disabling and costly of all pain complaints13 (i.e., those with more constant, chronic 
pain are more likely to experience interference with daily activities [e.g., work inside or 
outside the home] and physical functioning as well as health-related quality of life). The 
total mean years since last paclitaxel treatment for women in our sample was 
approximately 2 years. Because our sample included more women who had been treated 
with paclitaxel in the past compared to those on active treatment, our sample may have 
included more women experiencing a more chronic type of pain. Our correlative findings 
where greater intensity or distress of TIMP was associated with greater interference with 
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daily activities, worse physical functioning, and worse health-related quality of life suggest 
these facts about chronic pain and chronic musculoskeletal pain in particular may be 
applicable to TIMP experienced by ovarian cancer survivors. Pain is also known to be 
even more prevalent in individuals with psychiatric comorbidity and is a strong predictor of 
onset and persistence of depression; likewise, depression is a strong predictor of pain.16 
Comorbidity of pain and chronic conditions (e.g., sleep disturbance, anxiety, and 
depression) decrease active coping and negatively impact health-related quality of life, 
disability, and even response to treatment.16, 17 Our correlations support these facts may 
be true in our sample of women and may support patient-reported outcomes measures as 
an important endpoint in ovarian cancer clinical trials and in discussions with healthcare 
providers about therapy options and plans of care.8, 10 A prospective, longitudinal study 
continues to be the best recommendation for future research studies not only to better 
understand the seemingly variable and non-uniform nature of TIMP intensity and distress, 
but also the duration and temporal pattern of TIMP in order to better understand any 
underlying chronicity of TIMP and the role this chronicity may play in the associations 
between TIMP intensity and distress and patient-reported outcomes measures. 
Collectively, these findings add to the symptom science literature describing the 
TIMP symptom experience in cancer survivors and its likely impact on patient-reported 
outcomes. Additionally, these findings come at a time when recognition of patient-
reported outcomes is of growing research interest and requires attention to standardized 
measurement of health-related quality of life outcomes, as used in our study, in 
populations including cancer survivors.42-44 
Strengths and Limitations 
These preliminary findings provide new understanding of how TIMP intensity and 
distress are associated with patient-reported outcomes including interference with daily 
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activities, physical functioning, and health-related quality of life in women with ovarian 
cancer who were being or had been treated with paclitaxel chemotherapy. Information 
presented in this paper is important for nurses in understanding best clinical practice for 
TIMP symptom management in this population. 
Findings should be interpreted in the context of some limitations. This was a 
small pilot study and because of the small pilot sample, we were unable to control for 
potential confounding influences in the analyses. We recommend replication in a larger 
sample. Also, the study focused on women with ovarian cancer which limits 
generalizability to other types of cancer. Comorbid conditions such as osteoarthritis or 
degenerative arthritis or back pain, which were present in our sample of women, may 
have impacted our results; although we asked participants to answer TIMP-related 
questionnaires in thinking about their TIMP, it is unknown whether all women responded 
as instructed. Finally, differences between women who were actively undergoing 
treatment and those who had been treated in the past were not compared within the 
context of the findings presented in this paper.  
Implications for Research to Advance Practice 
Attention to TIMP and the impact of TIMP on patient-reported outcomes is 
important in ovarian cancer survivors. Inclusion of patient-reported outcomes as an 
endpoint in cancer clinical trials and in discussions with healthcare providers about 
therapy options and plans of care8, 10 is especially important in the case of ovarian 
cancer survivors who experience disease recurrence and life with active disease. Our 
pilot study provides preliminary evidence about the associations between TIMP intensity 
and distress and patient-reported outcomes including interference with daily activities, 
physical functioning, and health-related quality of life and health-related quality of life, in 
particular, appears to be an important patient-reported outcome to evaluate in women 
 110 
with ovarian cancer. Replication of our findings in larger sample sizes is recommended; 
however, TIMP may negatively impact the health-related quality of ovarian cancer 
survivors and these associations and potential impact on patient-reported outcomes 
measures should be considered by providers in clinical practice.  
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Table 4-1 
TIMP Phenotypes Based on BPI Intensity Ratings and Distress Ratings (N=15) 
Note. TIMP= Taxane-induced musculoskeletal pain; BPI= Brief Pain Inventory; 
Participant data are sorted according to phenotype and then participant number; Mild= 
all ratings in mild range (0 to 4); Mild to moderate= all ratings in mild (0 to 4) or moderate 
range (5 to 6); Moderate to severe= all ratings in moderate (5 to 6) or severe range (7 to 
10); Severe= all ratings in severe range (7 to 10); Variable= ratings from mild (0 to 4) to 
severe (7 to 10) range.   
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Table 4-2 
Spearman’s Correlations: TIMP Intensity and Distress with Patient-reported Outcomes 
 BPI 
Interference1 
PF 
102 
FACT-
G Total 
Score2 
FACT-G 
Physical2 
FACT-G 
Social2 
FACT-G 
Emotional2 
FACT-G 
Functional2 
BPI 
Intensity1 
       
Worst .59* -.44 -.46 -.55* -.32 -.52* -.30 
Least .67** -.77** -.80** -.67** -.78** -.63* -.51 
Average .74** -.76** -.79** -.86** -.63* -.60* -.54* 
Now .64* -.50 -.54* -.73** -.35 -.54* -.38 
Total .76* -.66** -.74** -.83** -.58* -.67** -.46 
Diary 
Intensity1 
       
Morning  .35 -.53 -.46 -.29 -.55 -.37 -.43 
Nighttime  .39 -.57 -.52 -.41 -.49 -.40 -.32 
Combined  .39 -.57 -.49 -.38 -.50 -.40 -.34 
BPI 
Distress1 
.81** -.62* -.67** -.76** -.48 -.68** -.47 
Note. TIMP= Taxane-induced musculoskeletal pain; BPI= Brief Pain Inventory; PF 10= 
Performance 10; FACT-G= Functional Assessment of Cancer Therapy- General;  
1higher scores = worse outcomes 
2higher scores = better outcomes 
*p < 0.05; **p < 0.01. 
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Table 4-3 
Patient-reported Outcomes across Phenotypes for TIMP Intensity and Distress 
 Mild 
 
n=4 
 
M (SD): 
range 
Mild to 
Moderate 
n=3 
 
M (SD): range 
Moderate to 
Severe 
n=1 
 
M 
Severe 
 
n=1 
 
M  
Variable 
 
n=6 
 
M (SD): range 
BPI-
Interference1,3 
1.5 (1.9): 
0.3 to 4.3 
4.3 (2.3): 2.3 
to 6.9 
7.3 8.4 5.1 (3.1): 0.0 
to 8.3 
 
PF102,3 21.3 (4.6): 
15 to 26 
 
18.3 (6.5): 
12 to 25 
 
16 10 17.7 (3.5): 
14 to 24 
 
FACT-G Total 
Score2,4 
89.8 (16.2): 
66 to 101 
 
65 (18.7): 44 
to 80 
 
46 37 73.8 (14.7): 
63 to 102 
 
FACT-G 
Physical2,4 
24 (2.2): 21 
to 26 
 
15.7 (4.6): 
13 to 21 
 
12 12 17.3 (5.1): 
13 to 26 
 
FACT-G Social2,4 25.3 (3.6): 
20 to 28 
 
21.3 (8.1): 
12 to 27 
 
8 11 24.2 (3.1): 
20 to 28 
 
FACT-G 
Emotional2,4 
22 (3.3): 17 
to 24 
 
16.7 (4.2): 
12 to 20 
 
9 8 17.8 (2.7): 
14 to 22 
 
FACT-G 
Functional2,4 
18.5 (7.9): 8 
to 25 
 
11.3 (4.5): 7 
to 16 
 
17 6 14.5 (5.7): 
11 to 26 
 
Note. TIMP= Taxane-induced Musculoskeletal pain; BPI= Brief Pain Inventory; PF 10= 
Performance 10; FACT-G= Functional Assessment of Cancer Therapy- General; M= 
mean; SD= standard deviation, CI= confidence interval 
 
1n=14 
2n=15 
3higher scores = worse outcomes 
4higher scores = better outcomes 
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CHAPTER 5 
The purpose of this dissertation was to address a gap in the cancer literature 
regarding the symptom experience of TIMP in women with ovarian cancer who were 
being or had been treated with paclitaxel-containing regimens. The Aims of this study 
provided new information regarding TIMP by (1) describing the TIMP symptom experience 
(intensity, distress, duration, location, quality, temporal pattern, aggravating and alleviating 
factors, and pain management); (2) identifying the associations between TIMP (intensity, 
distress) and co-occurring symptoms (pain [general], peripheral neuropathy, impaired 
sleep, fatigue, emotional distress, and/or hot flashes); and (3) identifying the associations 
between TIMP (intensity, distress) and patient-reported outcomes (interference with daily 
activities, physical functioning, and health-related quality of life). The dissertation results 
are presented in this dissertation in three manuscripts. Manuscript 1 (Chapter 2), which 
has been published in Cancer Nursing, is a review of the state of the science of TIMP1; 
Manuscript 2 (Chapter 3) is a presentation of the description of the TIMP symptom 
experience and the associations between TIMP (intensity, distress) and co-occurring 
symptoms; and Manuscript 3 (Chapter 4) is the presentation of the associations between 
TIMP (intensity, distress) and patient-reported outcomes. This final chapter synthesizes 
the key findings from all three manuscripts, the strengths and limitations of the 
dissertation study, and recommendations for future research. 
Synthesis of Key Findings 
First, the need for research describing TIMP was identified by the primary author 
through an extensive literature search. In research on TIMP, authors provide little 
consistency in the use of terms to signify muscle and/or joint pain following taxane 
chemotherapy.1 Also, measurement has been largely limited to toxicity grading scales 
which provides a limited assessment of the TIMP symptom experience (i.e., 
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assessments are largely limited to intensity) and, subsequently, these assessments do 
little to inform potentially effective interventions for managing TIMP. Research on 
descriptions of TIMP should initially include an evaluation of all dimensions of the 
symptom experience including intensity, distress, duration, location, quality, temporal 
pattern, aggravating and alleviating factors, and pain management. Furthermore, 
research which provides a better understanding of the associations between TIMP and 
co-occurring symptoms and TIMP and patient-reported outcomes is important in 
informing the development, timing, and testing of interventions to manage TIMP. Guided 
by the Theory of Symptom Management and the Theory of Unpleasant Symptoms, 2-4 
this manuscript provided the initial next steps in quantifying preliminary descriptions of 
the dimensions of the TIMP symptom experience and associations between TIMP and 
co-occurring symptoms and TIMP and patient-reported outcomes to better understand 
TIMP and to positively impact the health-related quality of life of cancer survivors. 
Quantifying the preliminary description of TIMP and the associations between TIMP and 
co-occurring symptoms and TIMP and patient-reported outcomes was accomplished 
through the completed pilot study described in Chapter 3. 
Second, through data analysis of the proposed pilot study, a multi-dimensional 
description of TIMP in women with ovarian cancer who were being or had been treated 
with paclitaxel-containing regimens was completed. A key feature of this description was 
the large variability seen in the women’s experiences of TIMP intensity and distress. 
However, for most women included in this study, the clinical presentation of TIMP 
included pain that was mild to severe in intensity, nearly constant in duration, aching in 
nature, diffusely located throughout the body, variable in temporal pattern, aggravated by 
everyday functions such as walking and sitting, and not fully relieved by pain medications. 
Prior research on TIMP is limited in its descriptions of TIMP1, 5 and, before now, specific 
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details of TIMP intensity, distress, duration, location, quality, temporal pattern, 
aggravating and alleviating factors, and pain management have been unspecified in the 
literature. The multi-dimensional description of TIMP this dissertation provides is useful 
for assessing and managing this type of treatment-related pain and may serve as a 
benchmark or comparison for future prospective, longitudinal TIMP research studies.   
Third, associations between TIMP (intensity, distress) and co-occurring 
symptoms were identified. This dissertation has provided preliminary evidence that 
greater TIMP intensity and distress was associated with greater intensity or interference of 
co-occurring symptoms, suggesting TIMP, like other cancer treatment-related symptoms, 
may occur within a symptom cluster of general pain, peripheral neuropathy, sleep 
disturbance, anxiety, depression, fatigue, and hot flashes. These findings support the 
idea that assessment of co-occurring symptoms should be incorporated into clinical care 
in order to better delineate appropriate treatment options. Learning from patients which 
symptoms co-occur reliably and are distressing continues to remain an important priority 
for future research studies.6 
Finally, associations between TIMP (intensity, distress) and patient-reported 
outcomes were identified. This dissertation has provided preliminary evidence that 
greater TIMP intensity and distress was associated with greater interference with daily 
activities, worse physical functioning, and worse health-related quality of life. Research on 
chronic pain suggests pain is among the most common reasons for temporary and 
permanent work disability7, 8 and musculoskeletal pain, in particular, is the most disabling 
and costly of all pain complaints.8 Furthermore, co-morbidity of pain and chronic conditions 
such as depression are known to decrease active coping and negatively impact health-
related quality of life, disability, and response to treatment.9, 10 Correlative evidence from 
this dissertation identifying greater TIMP intensity and distress was associated with 
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greater interference with daily activities, worse physical functioning, and worse health-
related quality of life suggests facts about chronic pain and chronic musculoskeletal pain 
and its impact on patient outcomes may be applicable to the TIMP experienced by women 
with ovarian cancer. Recognition of patient-reported outcomes and their use in clinical 
research remains an important priority, especially in studies of cancer survivors. Additional 
studies focusing on the socioeconomic and social impact of TIMP in this population of 
cancer survivors is needed. 
Strengths and Limitations of the Dissertation 
This dissertation addressed the important national research priority of symptom 
management set forth by the National Cancer Institute (NCI) Office of Cancer 
Survivorship,11 the National Institute of Nursing Research (NINR),12 the American Cancer 
Society (ACS),13 the Institute of Medicine (IOM),14 and the Oncology Nursing Society 
(ONS).15 Additionally, this dissertation used patient-reported outcomes measures at a time 
when recognition of patient-reported outcomes, supported by the National Institutes of 
Health (NIH), is of growing research interest and requires attention to standardized 
measurement of health-related quality of life outcomes in populations including cancer 
survivors.16-19  
This dissertation was also the first study to fully describe the TIMP symptom 
experience including the dimensions of intensity, distress, duration, location, quality, 
temporal pattern, aggravating and alleviating factors, and pain management in women 
with ovarian cancer who were being or had been treated with paclitaxel-containing 
regimens. Before now, these dimensions of TIMP have been unspecified in the literature. 
Additionally, this dissertation was the first study to identify associations between TIMP 
(intensity, distress) and co-occurring symptoms and TIMP (intensity, distress) and patient-
reported outcomes. Preliminary findings identified by this dissertation provide a new 
 124 
understanding of the dimensions of TIMP; how TIMP intensity and distress are 
associated with co-occurring symptoms including general pain, peripheral neuropathy, 
impaired sleep, fatigue, emotional distress, and hot flashes; and how TIMP intensity and 
distress are associated with patient-reported outcomes including interference with daily 
activities, physical functioning, and health-related quality of life.  
The findings of this dissertation should be interpreted within the context of its 
limitations. This was a small pilot study which limited the ability to control for potential 
confounding influences in the analyses. Replication of study findings in larger samples 
with a comparison group of non-cancer women with chronic musculoskeletal pain is 
recommended. Women with ovarian cancer were the focus of this dissertation, which 
limits the generalizability of the findings to other types of cancer survivors also treated 
with paclitaxel-containing regimens and experiencing TIMP. Due to the sample size and 
because potential confounding influences could not be controlled for in the analyses, 
comorbid conditions, such as osteoarthritis or degenerative arthritis or back pain which 
were present in our sample of women, may have influenced the results. Participants in 
this study were asked to answer all TIMP-related questionnaires in thinking about their 
TIMP, but it is unknown whether all participants responded as instructed or had the 
ability to distinguish between the types of pain they were experiencing. Finally, due to 
the small sample size, differences between women who were actively undergoing 
paclitaxel treatment and those who had been treated in the past were not compared 
within the context of the findings presented in this dissertation.  
Recommendations for Future Research 
Future research describing TIMP and the associations between TIMP and co-
occurring symptoms and TIMP and patient-reported outcomes is warranted in cancer 
survivors. The findings from this dissertation largely illustrated the appreciable variability 
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in clinical reports of TIMP. Prospective, longitudinal studies describing TIMP and its 
variability could improve the assessment and management of this treatment-related 
symptom in cancer survivors. The addition of a non-cancer control group with chronic 
musculoskeletal pain is also recommended. In addition, a prospective, longitudinal 
approach would provide the perspective to best inform the development, timing, and 
testing of effective interventions to manage TIMP in cancer survivors. Learning from 
patients which symptoms co-occur reliably and are distressing continues to remain an 
important priority for future research studies, 6 and additional research on TIMP is well 
aligned with this important recommendation for symptom science research. Similarly, 
recognition of patient-reported outcomes and their use in clinical research remains an 
important research priority.16-19 Additional research on TIMP is also well aligned with this 
recommendation from NIH. Finally, this dissertation provided the first multi-dimensional 
description of TIMP and this description may serve as a benchmark or comparison for 
future TIMP research studies.   
Conclusions 
Cancer and cancer treatment-related symptoms can profoundly affect an 
individual’s health-related quality of life throughout survivorship.20 Healthcare providers, 
and oncology nurses in particular, play an important role in assessing and managing 
distressing treatment-related symptoms experienced by cancer survivors. This dissertation 
called attention to TIMP, an important treatment-related symptom experienced by cancer 
survivors, and provided the initial steps toward better understanding the dimensions of this 
symptom and the associations between this symptom and co-occurring symptoms and 
patient-reported outcomes. Among women with ovarian cancer who were being or had 
been treated with paclitaxel-containing regimens, TIMP is mild to severe in intensity and 
is moderately distressing. TIMP intensity and distress are associated with co-occurring 
 126 
symptoms and patient-reported outcomes. Future research describing the 
multidimensional experience of TIMP and the associations between TIMP and co-
occurring symptoms and TIMP and patient-reported outcomes is warranted to positively 
impact the health-related quality of life of cancer survivors affected by TIMP.   
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2014 PhD Leadership Fellowship Award, Indiana University School of 
Nursing, Indianapolis, IN 
2013 – 2014 Research Incentive Funding, Indiana University School of Nursing, 
Indianapolis, IN 
2013 – 2014 Predoctoral Fellowship, Behavioral Cooperative Oncology Group, 
Indiana University School of Nursing, Indianapolis, IN 
2013 Academic Achievement Award, Indiana University School of 
Nursing, Indianapolis, IN 
2002 National Society of Collegiate Scholars, Purdue University, West 
Lafayette, IN 
2002 Golden Key International Honor Society, Purdue University, West 
Lafayette, IN 
 
PUBLICATIONS 
Peer Reviewed (articles) 
Carter-Harris, L., Davis, L.L., & Rawl, S.M. (2016). Lung cancer screening participation: 
Developing a conceptual model to guide research. Research and Theory for Nursing 
Practice, 30(4), 333-352. PMID: 28304262 
Otte, J.L., Davis, L.L., Carpenter, J.S., Krier, C., Skaar, T., Rand, K.L., Weaver, M., 
Landis, C., Cherynak, Y., & Manchanda, S. (2016). Sleep disorders in breast cancer 
survivors. Supportive Care in Cancer, 24(10), 4197-4205. PMID: 27146391 
Davis, L.L., Kroenke, K., Monahan, P., Kean, J., & Stump, T.E. (2016). The SPADE 
symptom cluster in primary care patients with chronic pain. The Clinical Journal of Pain, 
32(5), 388-393. PMID: 26295379 
Davis, L.L., Carpenter, J.S., & Otte, J.L. (2016). State of the science: Taxane-induced 
musculoskeletal pain. Cancer Nursing, 39(3), 187-196. PMID: 26034876 
Davis, L.L. & Carpenter, J.S. (2015). A systematic review of nonpharmacologic 
interventions for treatment-related symptoms in women with ovarian cancer. Clinical Journal 
of Oncology Nursing, 19(5), 535-542. PMID: 26414573 
Philips, C.R. & Davis, L.L. (2015). Psychosocial interventions for adolescents and young 
adults with cancer. Seminars in Oncology Nursing, 31(3), 242-250. PMID: 26210202 
 
Peer Reviewed (abstracts) 
Davis, L.L. & Carpenter, J.S. (2015). A Systematic Review of Interventions for Treatment-
related Symptoms in Ovarian Cancer. Oncology Nursing Forum, 42(2), E128. 
Davis, L., Otte, J., & Carpenter, J. (2013). Symptom Management in Ovarian Cancer: A 
Review of the Theory of Symptom Self-Management. Oncology Nursing Forum, 40(6), 
E427. 
Davis, L. & Carpenter, J.S. (2012). Mindfulness-based Stress Reduction in Oncology 
Patients: Development of a Tool for Self-directed Patient Care Decisions. Oncology Nursing 
Forum, 39(6), E513. 
  
PRESENTATIONS 
Peer Reviewed 
Otte, J. L., Manchanda, S., Skaar, T., Rand, K., Weaver, M., Chernyak, Y., Davis, L., 
Krier, C., Carpenter, J. S. (Jun. 2015). “Oncology provider knowledge and practice for 
sleep problems in cancer patients and survivors,” poster presentation, American 
Academy of Sleep Medicine, Seattle, WA. 
Davis, L.L., & Carpenter, J.S. (Apr. 2015). “A Systematic Review of the Quality of Non-
pharmacologic Interventions for Treatment-Related Symptoms in Ovarian Cancer,” podium 
presentation, Oncology Nursing Society, Orlando, FL. 
Davis, L.L., Otte, J.L., & Carpenter, J.S. (Apr. 2015). “State of the Science: Taxane-
Induced Musculoskeletal Pain,” poster presentation, Midwest Nursing Research Society, 
Indianapolis, IN. 
Otte, J.L., Manchanda, S., Rand, K.L., Skaar, T., Weaver, M., Krier, C., Davis, L., & 
Carpenter, J.S. (Apr. 2015). “Preferred Treatments for Sleep Complaints by Breast 
Cancer Survivors,” poster discussion, Midwest Nursing Research Society, Indianapolis, 
IN. 
Davis, L.L., Otte, J.L., & Carpenter, J.S. (Sept. 2014). “Taxane-Induced Musculoskeletal 
Pain: An Integrative Review,” poster presentation, Council for the Advancement of 
Nursing Science, Washington, DC. 
Davis, L.L., Otte, J.L., & Carpenter, J.S. (Jun. 2014). “Taxane-Induced Musculoskeletal 
Pain: An Integrative Review,” poster presentation, St. Vincent Health, Indianapolis, IN. 
Davis, L.L., Otte, J.L., & Carpenter, J.S. (Jun. 2014). “Taxane-induced Musculoskeletal 
Pain in Women with Ovarian Cancer: An Integrated Conceptual Model for Guiding 
Research in Oncology Symptom Management,” poster presentation, St. Vincent Health, 
Indianapolis, IN. 
Davis, L.L., Otte, J.L., & Carpenter, J.S. (May 2014). “Taxane-induced Musculoskeletal 
Pain in Women with Ovarian Cancer: An Integrated Conceptual Model for Guiding 
Research in Oncology Symptom Management,” poster presentation, Indiana University 
Health Melvin and Bren Simon Cancer Center, Indianapolis, IN. 
Davis, L.L., Otte, J.L., & Carpenter, J.S. (Nov. 2013). “Symptom management in ovarian 
cancer: A review of the theory of symptom self-management,” poster presentation, 
Oncology Nursing Society, Dallas, TX. 
Davis, L.L. & Carpenter, J.S. (Nov. 2012). “Mindfulness-based stress reduction in oncology 
patients: Development of a tool for self-directed patient care decisions,” poster 
presentation, Oncology Nursing Society, Phoenix, AZ. 
 
Invited 
Davis, L. (Feb. 2015). “Oncology Nursing,” guest lecturer, Indiana University School of 
Nursing, Bloomington, IN. 
 
FUNDING 
Grant/Fellowship  Conferring Organization Amount Dates 
Doctoral Degree  American Cancer Society $15,000 2016 - 2017  
Scholarship in Cancer  
Nursing Renewal 
Doctoral Degree  American Cancer Society $30,000 2014 - 2016 
Scholarship in Cancer 
Nursing 
PhD Leadership   IU School of Nursing   $1,000  2014 
Fellowship Award 
Research Incentive   IU School of Nursing   $20,000 2013 - 2015  
  
Funding 
Predoctoral Fellow, IU  Behavioral Cooperative   $60,536 2013 - 2015 
   Oncology Group 
      
 
COMMUNITY INVOLVEMENT 
11/2014  Volunteer, Discovery Ball Fundraiser, American Cancer Society, 
Indianapolis, IN 
10/2013  Volunteer, Making Strides against Breast Cancer Walk Fundraiser, 
American Cancer Society, Indianapolis, IN 
 
 
 
 
 
 
 
 
